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2. Summary 
 
Mesenchymal stem/ stromal cells (MSCs) isolated from mice have allowed to 
address some of the major issues that could not be investigated by using 
human MSCs. For this thesis, a thorough characterization of a previously 
described mouse MSC population, namely PαS MSCs (identified by 
expression of both PDGFRα and Sca1 antigens) was done. Using a 
developmental approach, the MSC-like cells were also identified in embryonic 
stages. We identified 4 subpopulations of PαS cells, based on the expression 
of the CD90 and CD73 markers. The flow-cytometry based analysis revealed 
different time points of the emergence of the different subpopulations of these 
cells during ontogeny. Using a Sox9-GFP reporter line, we were able to 
correlate these changes with the predominant chondrogenic and osteogenic 
processes during progression of mouse development and endochondral 
ossification. 
 
A developmental paradigm was used to characterize the “stem” like properties 
of PαS subpopulations in vitro from postnatal day P2, since a significant 
increase of this population was observed from E18.5 until P2 after birth. The 
conditions of the in vitro trilineage differentiation and chondrogenic 
differentiation were refined to achieve better results by mimicking the 
molecular pathways operating during limb development. Two subsets of PαS 
cells were discriminated by the expression of CD90 marker (PαS+CD90+ and 
PαS+CD90- subsets). These subsets were assessed for their in vivo fate by 
engrafting cartilage templates generated from these cells subcutaneously in 
nude mice. Strikingly, the cartilage models generated from the PαS+CD90+ 
subset remodeled completely to undergo endochondral ossification and the 
resulting bone ossicles were invaded by host-derived bone marrow cells. On 
the other hand, the cartilage models generated from the PαS+CD90- subset 
appeared to remodel only partially. No endochondral ossification was 
observed, but the expression of Sox9 persisted, which pointed to 
maintenance of chondrogenic potential. As in vivo functions of MSCs may 
depend on their interaction with HSCs in the stem cell niche, cartilage 
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templates generated from PαS subsets isolated at embryonic day E18.5 were 
also engrafted. This developmental stage coincides with migration of the first 
HSCs from fetal liver to the bone marrow. The remodeling of cartilage into 
bone was reduced and only small bone ossicles formed when cartilage 
templates from PαS+CD90+ cells were implanted.  
 
Thus, this study focuses on extensive characterization of PαS cells to identify 
new subpopulations and refining the conditions of multilineage differentiation 
in these subpopulations with a developmental approach. Emergence of these 
subpopulations during mouse development to contribute towards cartilage 
and bone lineage was determined by studying in detail their in vivo fates 
during endochondral ossification.   
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4. Introduction 
 
4.1 What is defined as Mesenchymal stromal/ stem cells? 
4.1.1 Historical perspective 
The term ‘MSCs’ was coined by Caplan for mesenchymal stem cells that are 
precursors of bone, cartilage and other mesodermal tissues (Caplan, 1991). 
These cells were speculated to reside in bone marrow (BM), which was used 
to determine its osteogenic potential (Tavassoli and Crosby, 1968; Bianco et 
al., 2008). Friedenstein and coworkers showed for the first time that the 
osteogenic potential of cells from bone marrow was actually inherent in a 
fraction of BM cells that adhered to the plastic in culture and have fibroblastic 
morphology (Friedenstein et al., 1968). These cells were able to give rise to 
colonies when plated in vitro that were termed as colony-forming unit 
fibroblasts (CFU-F). The CFU-F cell populations from bone marrow are 
thought to contain stem cells of non-hematopoietic lineage, the MSCs 
(Friedenstein et al., 1970, reviewed by Friedenstein et al., 1992). 
 
4.1.2 Definition of ‘MSC’ 
MSCs are defined as stem cells of non-hematopoietic lineage that adhere to 
plastic, are able to give rise to CFU-Fs and are multipotent (Pittenger et al., 
1999). Owing to heterogeneity in unfractionated MSC populations derived 
from bone marrow, common criteria to identify these cells are difficult. The 
minimal criteria to define MSCs by International Society for Cellular Therapy 
(ISCT) are illustrated in Fig. 1 (Dominici et al., 2006): 
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The listed markers in Fig. 1 do not identify a homogeneous mesenchymal 
stem cell population (Sabatini et al., 2005). In addition, ex vivo expansion of 
MSCs cause chromosomal abnormalities that could transform these cells 
such that they can no longer be considered as MSCs. Human MSCs display 
osteogenic potential at single cell level (Sacchetti et al., 2007). Nonetheless, 
the term ‘MSCs’ has remained controversial as a definitive proof of their 
‘‘stemness’’ by single-cell in vivo transplantation experiments has not been 
achieved (reviewed by Bianco et al., 2013).  
 
4.2 Human MSCs (hMSCs): concepts of tissue regeneration and its 
limitations 
Most of the criteria used to define MSCs were based on studies using human 
MSCs (hMSCs) and bone marrow cells. Initially, studies conducted with the 
aim to use hMSCs for ‘cell replacement’ therapies were hampered by the use 
of undefined MSC populations. Additional studies identified other tissue 
sources (e.g. dental pulp (Gronthos et al., 2002), umbilical cord blood (Erices 
et al., 2000), adipose tissue (Zuk et al., 2002) and skin (Shih et al., 2005), 
etc.) as sources for MSCs. The self-renewal capacity and multilineage 
potential of these MSCs varied a lot depending on the tissue sources 
(Sarugaser et al., 2009, reviewed by Keating, 2012). In addition, another 
consideration for regenerative therapy in using MSCs is their potential 
immunomodulatory properties, as these cells are known to influence the 
innate and adaptive immune system by altering the expression of 
Fig. 1 ISCT’s minimal criteria to define 
‘MSCs’: 
• Adherence to plastic 
 
• Expression of specific surface antigens 
(positive for: CD105, CD90 and CD73; 
negative for: CD45, CD34, CD11b, CD19 
and HLA class II/ HLA-DR) 
 
• Multilineage differentiation potential into:  
osteoblasts, adipocytes and chondrocytes. 
Adapted from (Le Blanc and Mougiakakos, 
2012) 
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inflammatory cytokines (Le Blanc and Ringden, 2007; Nauta and Fibbe, 2007; 
Uccelli et al., 2008, Tolar et al., 2010, Chen et al., 2011, reviewed by Keating, 
2012). Due to such limitations arising from undefined MSC populations, it was 
important to further characterize the hMSCs before using them as a cell 
source for therapeutic applications. Identification of additional MSC markers 
provided further functional insights into the nature of these cells. In addition to 
the markers mentioned before, several markers are expressed in human and 
mouse MSCs that are listed in Table 4.1:  
 
Markers  Full-form/ Alternate Names Reference 
CD90 Thy1 (Dominici et al., 2006) 
CD73 Nt5e, Ecto-59-nucleotidase (Dominici et al., 2006) 
CD105 Endoglin (Dominici et al., 2006) 
H-2-D H-2Db MHC class I alloantigen (Dominici et al., 2006) 
CD49a Alpha 1 beta 1 integrin (Boiret et al., 2005) 
CD49e Itga5, Integrin alpha-5, Fibronectin receptor (Colter et al., 2001) 
CD29 Itgb1, Integrin beta-1 (Delorme et al., 2008) 
CD44 Hyaluronate receptor (Delorme et al., 2008) 
CD51 Itgav, Integrin alpha-v, Vitronectin receptor (Foster et al., 2005) 
STRO-1  (Simmons and Torok-Storb, 
1991) 
CD140a Pdgfra, PDGF Receptor alpha (Delorme et al., 2008) 
CD140b Pdgfrb, PDGF Receptor beta (Tokunaga et al., 2008) 
CD106 Vcam1, Vascular Cell Adhesion Molecule 1 (Delorme et al., 2008) 
CD271 LNGFR, Low-affinity nerve growth factor 
receptor or LNGFR 
(Mabuchi et al., 2013) 
CD146 MCAM, melanoma cell adhesion molecule (Sacchetti et al., 2007) 
CD200 OX-2 membrane glycoprotein (Peister et al., 2004) 
SSEA-4 Stage Specific Embryonic Antigen 4 (Gang et al., 2007) 
CD47 Itgp, Integrin-associated protein (Foster et al., 2005) 
Sca1 Stem cell antigen 1 Morikawa et al., 2009 
Nestin  (Mendez-Ferrer et al., 2010) 
Mx1 Myxoma Resistance Protein 1, Interferon-
induced GTP-binding protein 
(Park et al., 2012) 
Prx1 Paired related homeobox 1 (Logan et al., 2002) 
LepR CD295, Leptin Receptor (Zhou et al., 2014) 
Table 4.1. List of markers that are expressed by human and mouse MSCs.  
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CD146 (melanoma cell adhesion molecule or MCAM) expressing hMSCs are 
isolated from the sub-endothelial fraction of human bone marrow stroma 
(Sacchetti et al., 2007). These cells form fibroblastic colonies and are distinct 
from other types of osteogenic fibroblast-like cells. Upon subcutaneous 
implantation into nude mice, the CD146-positive cells form bony ossicles 
infiltrated by hematopoietic cells derived from the host. These findings 
provided a better understanding of the roles of bone marrow stromal cells 
(BMSCs) in establishing a hematopoietic microenvironment in vivo. Pinho and 
coworkers showed that a subset of CD146+ cells in the BM express Nestin, 
CD51 and PDGFRα and have a high self-renewal potential as assessed by 
transplantation in immunodeficient mice (Pinho et al., 2013). These cells are 
also able to form bony ossicles that recruit murine hematopoietic cells 
enriched in HSPCs (hematopoietic stem/progenitor cells). Another study 
identified an hMSC population by a combination of LNGFR, VCAM-1 and 
THY-1 markers that allows enrichment of a highly clonogenic population of 
hMSCs from bone and marrow (Mabuchi et al., 2013). These findings provide 
a deep insight into the possible origin, localization and roles of MSCs in the 
BM stroma and their interactions with HSPCs to regulate the activity of stem 
cell niche. MSCs are now routinely isolated from bone marrow using FACS 
based prospective isolation that is based on a combination of surface markers 
(Fig. 2). 
 
 
 
Fig. 2. Isolation of MSCs. (A) Classical method relies on plastic adherence of BM cells 
followed by long-term expansion to eliminate the majority of non-adherent hematopoietic cells 
and select adherent colony forming cells as MSCs. (B) FACS based isolation of MSCs using 
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standard surface markers, without the need for long-term culture. This procedure allows 
isolation of naïve, more homogeneous and multipotent MSCs, free of contaminating 
hematopoietic cells. Adapted from (Mabuchi et al., 2013). 
 
Despite of recent progresses, the field addresses several limitations for 
identification of hMSCs. These cells still remain a very heterogeneous 
population, which may also lead to donor-to-donor variations in regenerative 
therapy. The in vitro expanded hMSCs may not recapitulate the in vivo 
physiological conditions and fate-mapping studies are not possible to track the 
role of hMSCs in vivo at the level of single cell. 
 
4.3 Mouse MSCs (mMSCs): Tools, genetic aspects and recent 
progress in the field 
As the rather complex architecture of bone, bone marrow and stem cell niches 
were uncovered, it was envisaged that MSCs likely reside in these niches as 
distinct cell populations with specific roles. To study this further, the mouse 
model was used as an attempt to identify the corresponding mouse MSC 
populations, gain insight into their functional roles and study their short and 
long-term contributions to different developing tissues by cell lineage-tracing 
experiments. In addition, the available mouse models provide excellent 
sources to identify novel surface markers for better MSC populations. Mice 
can easily be genetically modified and fluorescent reporter lines can be used 
for cell lineage tracing which provides important insights into the stemness 
and fates of non-committed MSCs and mesenchymal progenitors committed 
to specific lineages.  
 
4.3.1 Identification of new surface markers for mMSCs 
Identification of murine MSC markers began with the observation that 
unfractionated mouse bone marrow also contains adherent cells with 
clonogenic capacity in culture. These studies also showed that distinct stem 
cells in the bone marrow give rise to either hematopoietic or mesenchymal 
stem cells (Koide et al., 2007). Besides these standard markers used to 
define MSCs (Dominici et al., 2006), additional markers used to study human 
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MSCs are also differentially expressed in mouse mesenchymal cell 
populations. A list of the markers used to characterize mouse MSCs is 
provided in Table 4.1. 
 
The combination of PDGFRα and Sca1 (PαS) marks a specific MSC-like 
subpopulation in the bone marrow and among the cells isolated from compact 
bone (Morikawa et al., 2009; Houlihan et al., 2012). These cells are highly 
enriched for CFU-Fs, proliferate fast and can be induced to differentiate into 
chondrocytes, osteocytes and adipocytes (trilineage differentiation). In 
agreement with what has been shown for CD146+ human MSCs, these 
studies point to an interactive role of mMSCs in regulating and maintaining the 
hematopoietic stem cell niche (Morikawa et al., 2009; Mabuchi et al., 2013). 
The identification of PαS cells is one of the first steps in the direction to 
identify a bona-fide mMSC population in mouse adult bones. However, Sca1 
is not expressed in hMSCs, which renders direct comparison of human MSC 
populations with Sca1+ mouse MSCs difficult. Recently, CD200 marker, which 
is expressed by human bone marrow cells with osteogenic properties 
(Delorme et al., 2008), has been used as a part of a signature 
(CD45−Ter119−AlphaV+Thy+6C3−CD105+CD200+) to identify mouse skeletal 
stem cells (mSSCs) with stem cell-like properties. These mSSCs self-renew, 
are multipotent and differentiate predominantly into cartilage upon 
engraftment in the kidney capsule of immunosuppressed mice (Chan et al., 
2015). These mSSCs are defined as rare pro-chondrogenic progenitors 
residing in the bone marrow. 
 
4.3.2 Mouse genetic tools to study the fates of mMSCs in vivo 
While it is impossible to study the lineage commitment of hMSCs, mice are 
well suited for this purpose by combining inducible fluorescent proteins 
expression to track the fates of specific cell populations for fate mapping 
(Mendez-Ferrer et al., 2010; Park et al., 2012; Greenbaum et al., 2013; Zhou 
et al., 2014). One of the major breakthroughs is the identification of a MSC 
population marked by Nestin expression (nestin-GFP mice). Nestin positive 
cells encompass cells from bone marrow fraction with CFU-F activity and also 
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reside in the BM stroma to support the hematopoietic stem cell niche 
(Mendez-Ferrer et al., 2010). Nestin positive cells form non-adherent 
mesenspheres and display self-renewal capacity in serial transplantation 
experiments. Nes-GFP+ cells also express several other markers of HSC 
maintenance, some of which are also expressed by PαS cells. Some of these 
markers of HSC maintenance are listed in Table 4.2:  
 
Markers  Full-form/ Alternate Names Reference 
Cxcl12 C-X-C motif chemokine 12, Stromal-derived 
factor-1 (SDF-1) 
(Greenbaum et al., 2013) 
Kitl Stem cell factor/kit-ligand (Mendez-Ferrer et al., 2010) 
Angpt1 Angiopoietin-1 (Sacchetti et al., 2007) 
Il-7 Interleukin-7 (Mendez-Ferrer et al., 2010) 
Vcam1 Vascular cell adhesion molecule-1 (Mabuchi et al., 2013) 
Spp1 Osteopontin (Mendez-Ferrer et al., 2010) 
Table 4.2. List of markers that are expressed by MSCs during HSC maintenance.  
 
 Specific depletion of Nestin positive cells results in severe reduction (by 
~50%) of bone marrow HSCs (CD48−Lin−Sca-1+c-kit+ (LSK) cells and CD150+ 
CD48− LSK cell). These HSCs also have low capacity to home in the bone 
marrow. Interestingly, an MSC subpopulation based on expression of CD51 
and PDGFRα (CD51+PDGFRα+ double positive cells) are a fraction of nestin+ 
cells in mice and can be isolated from human (Pinho et al., 2013). These 
evidences show a possible interaction of HSCs with MSCs to maintain the 
stem cell niche in bone marrow.  
 
In addition, a recently published study used a more progenitor/ stem cell like 
Mx1+ bone marrow stromal cells that are fate-restricted and have perivascular 
origin. These cells replace the osteoblastic cells during mice development and 
take part in bone maintenance and regeneration (Park et al., 2012). The Mx1+ 
cells replaces the osterix labeling preosteoblasts and can be transplanted at 
the site of bone injury to migrate and recover injured bones. Another study 
used a fraction of stromal cells in bone marrow that expresses CXCL12 
(stromal-derived factor-1, SDF-1) that are abundant in the perivascular 
compartment of bone marrow. CXCL12 is a factor that is known to have 
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supportive role in maintaining HSCs and lymphoid progenitors in the bone 
marrow (Tokoyoda et al., 2004). The study shows that specific deletion of 
Cxcl12 in bone marrow subpopulations leads to the loss of hematopoietic 
progenitor cells (HPCs) and B-lymphoid progenitors from the bone marrow. 
These data suggest that the expression of CXCL12 is essential in maintaining 
HSC pool and involves the stromal component in the bone marrow for its 
development and maintenance. Interestingly, in this study, it is also shown 
that about 50% of PαS cells are targeted by Prx1-Cre that included a 
subpopulation of cells expressing intermediate levels of CXCL12 (Greenbaum 
et al., 2013).  
 
Furthermore, Leptin Receptor (LepR) was recently shown to mark ~0.3% of 
the bone marrow cells, mainly in arterioles and sinusoids. LepR can be used 
for FACS sorting to isolate highly clonogenic population of MSCs that co-
expressed PDGFRα, CD51 and Prx1 (Zhou et al., 2014). LepR+ cells were 
previously also identified in perivascular stromal cells and these cells were 
shown to produce Stem cell factor (Scf) and Cxcl12 within the bone marrow 
compartment (Ding and Morrison, 2013). Fate mapping of LepR+ cells in Lepr-
cre; tdTomato; Col2.3-GFP triple transgenic mice showed that these cells are 
a very rare population prior to birth. However, in 2 months old mice, LepR+ 
cells were easily detectable in the bone marrow fraction of the meta- and 
diaphysis that increased sharply with age. Clonal expansion of LepR+ cells in 
culture and their subsequent subcutaneous engraftment resulted in formation 
of bony ossicles with host-derived hematopoiesis. LepR+ cells also 
contributed to the bone, cartilage and adipocyte compartment following intra-
femoral injection in sub-lethally irradiated mice. In older mice, LepR+ cells 
were detected mostly in bone marrow adipocytes, while the adipocytes in the 
periosteum did not contain LepR+ cells, which pointed to a distinct origin of 
these cells.  
 
These lineage-tracing studies show that the MSCs that reside in the bone 
marrow stroma contribute predominantly to the osteocyte and adipocyte, but 
less to chondrogenic lineage. Recently, it was shown that expression of the 
bone morphogenetic protein (BMP) antagonist Gremlin 1 (Grem1+) marks 
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osteochondroreticular (OCR) stem cells within the bone marrow (Worthley et 
al., 2015). Grem1+ cells are distinct from perisinusoidal Nes-GFP+ cells and 
are able to give rise to osteoblasts, chondrocytes and reticular marrow 
stromal cells, but not adipocytes. Of note, Gremlin 1 is required for skeletal 
development (Zuniga, 2015) and bone homeostasis postnatally (Canalis et al., 
2012).  
 
Together, these and many other studies have provided deep insights into the 
molecular signature and potential diversity of MSCs. Identification of new 
surface markers resulted in isolation and characterization of different 
subpopulations of MSCs. Mouse PαS cells isolated from compact long bones 
are a rare subpopulation that appear to satisfy many of the defining criteria for 
MSCs based on their properties. However, in vivo marker and fate mapping 
analysis also shows that the in vivo functionality of MSC subpopulations may 
differ from their in vitro properties. This is a likely consequence of these MSCs 
interacting with HSCs, being part of stem cells in the niche and/ or other 
stromal cells in the niche. Most importantly, these studies also provided the 
insight into the ontology of the different MSC subpopulations during fetal and 
postnatal mouse development. Whether the mouse MSC populations and 
their roles are orthologous to human MSCs remain to be determined. 
 
4.4 Origin for tissues of mouse MSCs 
Most of the markers expressed by MSCs are also expressed by other cell 
types, such as fibroblasts. It has, thus, become an important topic of debate to 
discuss the origin of MSCs in order to specify the site of the tissue as a 
source of specific type of MSCs.  
 
4.4.1 Recent efforts to localize MSCs in bone marrow  
Recent efforts have indicated that MSCs may reside in the perivascular space 
of bone marrow (Morikawa et al., 2009; Mendez-Ferrer et al., 2010). Others 
indicated subendothelial region in the BM sinusoids as the origin of MSCs 
(Sacchetti et al., 2007).  During embryonic development, the primitive skeletal 
stem and progenitor cells likely reside outside the bone marrow cavity in the 
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perichondrium and periosteum. The primitive bone marrow stromal cells and 
the skeletal progenitor cells invade the developing cavity as the blood vessels 
are formed (Fig. 3). The MSCs located in the bone marrow after birth reside in 
the proximity of the blood vessels of subendothelial origin that are called 
sinusoids. However, it has been difficult to locate these cells in vivo. MSCs 
interact with HSCs and other hematopoietic cells in and around the sinusoids 
to maintain a niche microenvironment that support hematopoiesis, as well as 
development of osteoblasts and adipocytes (Fig. 3A, B). The development of 
bone marrow stoma is a complex process and the HSCs-MSCs interactions 
regulate the niches located in the perivascular space of the bone marrow 
stroma (reviewed by Bianco et al., 2013) (Fig. 3). The complexity of the bone 
marrow stroma is increasingly revealed by the identification of an increasing 
number of types and subpopulations of MSCs that function in regulating the 
stroma composition, together with their functional interaction with HSCs. 
Hence, a better understanding of the structure and function of BM stroma is a 
pre-requisite for attempts to mobilize these cells for regenerative medicine.  
 
 
Fig. 3. MSCs in the bone marrow stroma. (A) Blood vessels invade the primitive stroma 
cavity while skeletal progenitors generate osteoblasts to form bone and bone collar. 
Hematopoietic progenitors occupy the space in the sinusoidal blood vessel, along with 
primitive bone marrow stroma. (B) The MSCs reside in the perisinusoidal space and interact 
with HSC and other hematopoietic cells. Osteoblasts mature into osteocytes and form the 
bone trabeculum. Pericytes and adventitial reticular cells form a niche with HSCs and MSCs, 
which express a combination of markers (yellow box). Adipocytes fill the bone marrow 
stroma. Adapted from (Bianco et al., 2013).  
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4.4.2 Adipogenic differentiation: Late fates of MSCs in bone marrow? 
The adipogenic differentiation of MSCs in vitro follows the step-wise induction 
that differentiate MSCs into preadipocytes, which then mature into adipocytes 
that accumulate lipid droplets that are synthesized and stored in adipocytes. 
Several studies have shown that insulin, in combination with Dexamethasone 
and indomethacin induces differentiation of MSCs into adipocytes in culture 
(Zuk et al., 2002; Zhang et al., 2012). Dexamethasone, a synthetic 
glucocorticoid agonist acts as a stimulating agent (Grigoriadis et al., 1988) 
while indomethacin, a non-steroidal anti-inflammatory drug, induces PPARγ 
(Peroxisome proliferator-activated receptors alpha and gamma, (Lehmann et 
al., 1997)). Insulin binds to IGF-1 (insulin-like growth factor-1), the receptors 
of which are expressed by preadipocytes. This induces phosphorylation of the 
cAMP response element-binding protein (CREB) via cAMP and 
phosphatidylinositol-3 kinase (PI3K). CREB activates the expression of the 
CCAAT/enhancer binding protein alpha (C/EBPα) and PPARγ, which together 
promote adipogenesis (Hammarstedt et al., 2005; Rosen, 2005).  
 
The differentiation of MSCs into adipocytes has been linked to aging. LepR+ 
MSCs were shown to contribute to the adipocyte lineage in adult bone 
marrow. This contribution of LepR+ cells increased in older mice upon injury 
(Zhou et al., 2014). It has been suggested that osteogenic and adipogenic 
fates are determined at the expense of each other and mainly regulated by 
the balance of the Runx2 and PPARγ transcriptional regulators (Pei and 
Tontonoz, 2004; Muruganandan et al., 2009; James, 2013). The bone 
regenerative capacity declines with age, while the adipogenic fates become 
more prominent. This “adipogenic switch” of MSCs results in increased 
production of fat cells in the aging bone marrow (Pei and Tontonoz, 2004; 
Muruganandan et al., 2009, Lepperdinger, 2011; reviewed by James, 2013). 
 
4.5 Limb development: patterning, proliferation and differentiation 
The vertebrate limb bud has been used as a genetic model to study the 
molecular pathways involved in transcriptional regulation of cell proliferation 
and specification (Fig. 4). As most cells in the developing limb bud are of 
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mesenchymal origin, molecular pathways involved in proliferation and 
specification of these limb bud mesenchymal progenitors (LMPs) are likely of 
relevance to chondrogenic and osteogenic differentiation of MSCs. Fig. 4 
summarizes the patterning of embryonic limb formation that leads to 
development of skeletal elements in adult: 
 
 
Fig. 4 Limb bud development. (A) SEM image of a mouse embryo at E10.5 stage. The 
enlarged inset shows the forelimb bud with the proximo-distal (PD) and antero-posterior (AP) 
limb bud axes. The apical ectodermal ridge (AER) is indicated in green and the zone of 
polarizing activity (ZPA) is in the posterior mesenchyme. (B) The skeletal elements of a 
human arm. The stylopod forms humerus, the most proximal element; zeugopod forms the 
radius (anterior) and ulna (posterior); autopod forms the wrist (carpals), palm (metacarpals) 
and digit bones (phalanges) (Zeller et al., 2009). 
 
4.5.1 Molecular pathways regulating mesenchymal cell proliferation in 
developing limbs 
During the onset of limb bud, the distal most part of ectodermal epithelial layer 
forms apical ectodermal ridge (AER), which secretes several FGFs. These 
FGFs act as survival and proliferation factors for the underlying mesenchymal 
progenitors and instruct PD limb bud outgrowth and patterning (Niswander et 
al. 1994; Mariani et al., 2008). FGFs also maintain the expression of sonic 
hedgehog (SHH) in the posterior mesenchyme, which together with the BMP 
antagonist Grem1 assure survival and proliferation of LMPs, while BMPs 
induce their chondrogenic differentiation (reviewed by Zeller et al., 2009; 
Zuniga, 2015). In addition, ectodermal Wnts and AER-FGFs act in a 
synergistic manner to promote the proliferation and maintenance of 
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multilineage potential of LMPs in the distal mesenchyme of limb bud (Ten 
Berge et al., 2008). While LMPs in the distal mesenchyme continue to 
proliferate, cells in the proximal limb bud are no longer under the influence of 
Wnt and FGF signaling, and initiate chondrogenic differentiation under the 
influence of TGFβ/BMP signaling. 
 
4.5.2 Parallels between LMP and MSC proliferation 
The regulatory molecules that control the proliferation of LMPs have been 
used for promoting proliferation of MSCs in culture. In particular, their 
potential for long-term in vitro expansion and keeping these cells in 
undifferentiated state has been explored. However, these in vitro studies gave 
conflicting results. For example, treatment with Wnt3a to hMSCs in culture 
induced increased alkaline phosphatase (ALP) expression and decreased 
lipid droplet formation, which is due to Wnt3a inducing osteo-lineage 
commitment (Qiu et al., 2007). This study contradicted previous findings, 
which showed that Wnt3a is able to suppress osteogenic differentiation of 
hMSCs (Boland et al., 2004). FGF2 increases in vitro proliferation of the 
hMSCs, but again induces cells toward osteogenic lineage (Ito et al., 2007). 
These contradictory results in MSCs drove a sequential approach of 
exogenous application of these growth factors that mimic endogenous 
molecular pathways. Efforts are being made to provide the MSCs in culture as 
an indispensable source of multipotent stem/progenitor cells. These results 
underline the requirement of exposing MSCs to growth factors sequentially in 
a precise, time-controlled manner.  
 
4.6 Developmental regulation of the growth plate cartilage during 
endochondral ossification 
Endochondral ossification is the developmental program that controls long 
bone formation. This is the process by which cartilage templates undergo 
hypertrophy and are remodeled into bony tissue and longitudinal growth of 
bone progresses. The step-wise remodeling of the cartilage template into 
bone during endochondral ossification contrasts with the direct formation of 
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osteoblasts from mesenchymal condensation, without formation of a cartilage 
intermediate, which is called as intramembranous ossification.  
 
While endochondral ossification is typical for e.g. all limb skeletal bones, the 
flat bones of e.g. skull form by intramembranous ossification. The 
mesenchymal condensations are first step towards formation of the cartilage 
template required for the development of the endochondral skeleton. The 
following sections give an overview of molecular regulation of different steps 
during endochondral ossification: 
 
4.6.1 Role of Sox transcription factors in mesenchymal cell 
condensation and chondrogenic differentiation 
Following proliferative expansion of LMPs, several transcriptional regulators 
drive their specification towards osteo-chondrogenic progenitors in spatio-
temporally controlled manner. During osteo-chondrogenic commitment, LMPs 
start to express Sox9 and initiate mesenchymal condensation (Ng et al., 1997; 
Zhao et al., 1997). The Sox9 transcriptional regulator belongs to the HMG-box 
class DNA-binding protein that binds to the CCTTGAG sequence and is a 
master regulator of chondrogenesis (Akiyama et al., 2005). This study shows 
that conditional inactivation of Sox9 during limb bud development disrupts the 
mesenchymal cell condensation and formation of the cartilage templates of 
the future bone. 
 
Sox5 and Sox6 transcriptional regulators are also required for chondrogenesis 
after the initial mesenchymal condensation (Smits et al., 2001). This 
combination of Sox transcriptional regulators, i.e, the “Sox trio” (Sox5, Sox6 
and Sox9) is essential for chondrogenic differentiation. In particular, Sox9, 
which is activated first, controls the expression of Sox5 and Sox6 during 
subsequent steps of chondrogenic differentiation. The “Sox trio” promotes 
chondrocyte proliferation and suppresses their progression to hypertrophic 
stages and osteoblast differentiation (Fig. 5) (Ikeda et al., 2005).  
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Fig. 5. Role of Sox5, Sox6 and Sox9 in chondrogenic differentiation. Sox9 is essential before 
and after mesenchymal condensation; Sox5 and Sox6, the expression of which is controlled 
by Sox9, allow progression to proliferating chondrocytes. The Sox trio inhibits hypertrophy 
and further stages of chondrogenic differentiation (Ikeda et al., 2005). 
 
4.6.2 Molecular pathways controlling cartilage differentiation 
Chondrocytes in the developing cartilage templates are arranged in 
morphologically distinct zone, consisting of resting, proliferating and 
hypertrophic chondrocytes (Fig. 6) (Kozhemyakina et al., 2015).  
 
 
Fig. 6 distinct transition zones of developing cartilage template during long bone 
development. Adapted from (Kozhemyakina et al., 2015). 
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In addition to Sox transcription factors, chondrocytes express Collagen type-II 
and Aggrecan. The transforming growth factor β (TGFβ) superfamily that 
includes TGFβs and BMP ligands, together with Sox9 have been shown to 
regulate the differentiation of LMPs to chondroblasts and chondrocytes. 
TGFβ/BMP ligands bind to type I and type II serine/threonine kinase receptors 
and signal transduction involves the activation and nuclear localization of 
phosphorylated Smad proteins, which regulate the expression target genes 
(Derynck and Zhang, 2003; Shi and Massague, 2003; Feng and Derynck, 
2005). Combined deletion of SMADs 1, 5 and 8 in developing chondrocytes 
results in severe chondrodysplasia, in which the cartilage of the limbs are 
malformed and abnormal growth in long bone leads to shortened limbs. The 
result indicates that BMP signaling is essential for maintenance of 
chondrogenic fates (Retting et al., 2009). Similarly, SMAD4, a core mediator 
of canonical TGFβ/BMP signaling, is required for the formation of the Sox9-
positive digit ray primordia. Its inactivation in mouse limb buds blocks the 
aggregation of Sox9-positive osteo-chondrogenic progenitors and results in 
loss of collagen type-II (Retting et al., 2009; Benazet et al., 2012). These 
studies corroborate the essential roles and interactions of Sox9 and 
TGFβ/BMP signaling for initiating chondrogenesis. Three BMP ligands 
(BMP2, BMP4 and BMP7) are expressed in the limb bud and regulate 
chondrogenic differentiation. Deletion of Bmp2 and Bmp4 in the limb bud 
mesenchyme results in the loss of specific pre-cartilaginous condensations 
(Bandyopadhyay et al., 2006). Moreover, inactivation of both BMP receptors, 
BMPR1A and BMPR1B, results in loss of Sox9 expression and severe 
chondrodysplasia (Baur et al., 2000; Yi et al., 2000; Ovchinnikov et al., 2006). 
Further, genetic analysis showed that these BMP receptors have overlapping 
functions during chondrogenesis (Yoon et al., 2005). Using retroviral vectors 
to misexpress the BMP antagonist Noggin in chick limb buds, BMP ligands 
were shown to be required in a 2-step process of cartilage development, as 
the antagonist blocks both mesenchymal condensation and chondrogenic 
differentiation (Pizette and Niswander, 2000; Yoon et al., 2005). BMP 
signaling interacts with Sox genes to induce the expression of Col2a1 and 
Aggrecan during progression of cartilage differentiation (Chimal-Monroy et al., 
2003).  
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Furthermore, LMPs isolated from the proximal and distal limb bud from mouse 
embryo at E10.5 stage displayed distinct aggregation and condensation 
behaviors in culture. These cells appeared to have acquired distinct identities 
that allow them to sort themselves in culture, in agreement with the distinct 
identities of the future skeletal elements (Barna and Niswander, 2007). 
Inhibition of BMP signaling resulted in disruption of compaction and absence 
of cartilage nodules (Fig. 7). 
 
 
Fig. 7. Scheme of the cellular events LMPs undergo during osteo-chondrogenic commitment 
and formation of cartilage templates. Red arrows: movement of proximal limb progenitors; 
Green arrows: movement of distal limb progenitors (Barna and Niswander 2007). 
 
In addition, experimental evidence indicates that exposure of mesenchymal 
cells to TGFβ signaling primes LMPs for BMP-induced cartilage condensation 
(Karamboulas et al., 2010). When limb buds were dissected for distal and 
proximal LMPs and cultured in micromass, LMPs responded to BMP4 in 
differential manner. While the chondrogenic activity was lowered in LMPs 
from distal mesenchyme, it remained unaffected in the LMPs from proximal 
mesenchyme. When LMPs were isolated from the intermediate mesenchyme, 
the chondrogenic activity lowered by a lesser extent compared to that of 
LMPs from distal mesenchyme. This revealed a dose-dependent effect of 
BMP on the two LMP populations in the limb mesenchyme. The authors show 
that exposure of LMPs from distal limb bud to the TGFβ1 for only 4 hours is 
sufficient to overcome anti-chondrogenic effect of the BMP4 in culture. 
Furthermore, simultaneous addition of TGFβ1 and BMP4 inhibits 
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chondrogenesis, indicating that a sequential exposure of these molecules is 
required for positive modulation of chondrogenesis. Indeed, inhibition of TGFβ 
signaling results in loss of chondrogenesis response to BMP4, which points to 
the fact that TGFβ signaling primes LMPs for BMP-induced chondrogenesis. 
Supporting these results is the observation that all three TGFβ ligands are 
expressed in the mesenchyme of early limb buds. SMAD3, a downstream 
mediator of TGFβ signaling, is also expressed in the pre-chondrogenic 
mesenchyme (Lorda-Diez et al., 2009). Inactivation of Tgfbr2 in the limb bud 
mesenchyme results in defective development of long bones and joints (Seo 
and Serra, 2007), pointing to its requirement for chondrogenic differentiation. 
Sequential exposure of human and mouse MSCs to signals that induce 
formation of cartilage have had limited success. BM-derived hMSCs have 
been shown to respond to TGFβ signaling in pellet based culture setups and 
differentiate into hypertrophic cartilage (Pittenger et al., 1999). Priming of 
hMSCs in 3D culture with Wnt3a improves their responsiveness to TGFβ1-
induced chondrogenesis (Centola et al., 2013). The role of BMPs in 
chondrogenic differentiation of MSCs has remained largely elusive. Attempts 
to study the role of BMPs in osteogenic differentiation of hMSCs were non-
conclusive, but it was shown that BMPs induce the expression of the 
antagonist Noggin (Balk et al., 1997; Diefenderfer et al., 2003; Osyczka et al., 
2004). These results indicated that changes in extracellular signals alter the 
response of MSCs to BMPs and result in auto-regulation of BMP activity. 
Efforts to induce the afore-mentioned signaling pathway in a step-wise 
manner to mimic the developmental signaling networks and guide the MSCs 
towards their definitive fates are currently underway. 
 
4.6.3 The growth plate: distinctive features of articular and growth plate 
cartilage 
Based on functional properties, two distinct types of cartilage exist, namely, 
articular and growth plate cartilage. Articular cartilage consists of less 
proliferative and long-term stable chondrocytes that do not undergo 
hypertrophy. Articular chondrocytes neither produce extensive extracellular 
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matrix nor undergo apoptosis under normal conditions. They express the 
typical chondrocyte markers Col2a1 and Acan, in combination with sulfated 
glycosaminoglycans (GAGs). Progressive degradation of articular 
chondrocytes in joints, e.g. by apoptosis or progressive hypertrophy, results in 
osteoarthritis (OA). This disease is characterized by degenerating joints, 
accumulation of matrix-degrading enzymes, an increase in ossification and 
calcification. 
 
In contrast, growth plate chondrocytes are short-term proliferating 
chondrocytes that undergo hypertrophy and secrete large quantities of 
extracellular matrix, which ultimately results in their increased apoptosis. 
Continuation of hypertrophy results in remodeled cartilage, in which most of 
the extracellular matrix is eliminated by matrix-degrading enzymes, eventually 
promoting the longitudinal growth of the long bone rudiments (reviewed by 
Kronenberg, 2003). Genes expressed by chondrocytes during hypertrophy 
include collagen type X (Col10a1), Indian hedgehog (Ihh), alkaline 
phosphatase (Alp), matrix metalloproteinase (MMP-13), vascular endothelial 
growth factor (VEGF) and parathyroid hormone-related protein receptor 
(PTHrP-R) (Yoo et al., 1998; Sekiya et al. 2002; Pelttari et al., 2006).  
 
4.6.4 The signaling networks that regulate growth plate development 
The growth plates are located under the epiphyseal plate of developing bone 
(Fig. 8). Growth plate cells are arranged in vertical columns in a highly 
anisotropic manner, giving it a unique morphology (Kember and Sissons, 
1976; Rodriguez et al., 1992). Eventually, the proliferating chondrocytes 
flatten and transit to a pre-hypertrophic state. Signals then induce the 
transition from pre-hypertrophic to the hypertrophic stage, which is 
accompanied by an increase in volume due to increased extracellular matrix 
secretion and mineralization.  
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Fig. 8 Longitudinal section through a growth plate of mouse long bone depicting extracellular 
signals that regulate its development (E15.5 – E19).  (1) IHH and PTHrP act synergistically 
towards chondrocyte proliferation and maturation through a negative-feedback mechanism. 
IHH stimulates PTHrP transcription through derepression of GLI3, which mediates 
chondrocyte proliferation. PTHrP suppresses chondrocyte maturation associated with IHH 
expression.  (2) FGFR3 is a likely receptor for FGF9/18 to suppress chondrocyte proliferation 
in the growth plate late (3) BMPs expressed by both chondrocytes and perichondrial cells 
promote proliferation and maturation. (4) NOTCH signaling in chondrocytes promotes 
proliferation and maturation. (5) WNT5A expressed by pre-hypertrophic chondrocytes 
stimulates hypertrophy (Long and Ornitz, 2013). 
 
Several molecular cascades instruct to control the process of endochondral 
ossification. Indian hedgehog (Ihh), a hedgehog ligand and master regulator 
of bone development, is expressed by pre-hypertrophic chondrocytes located 
close to the proliferation zone, whereas parathyroid hormone-related protein 
(PTHrP) is expressed by peri-articular chondrocytes (Bitgood and McMahon, 
1995). It has been shown that IHH stimulates PTHrP expression in peri-
articular chondrocytes, which results in a feedback loop that regulates the 
growth plate and bone formation (Fig. 8) (Van den Heuvel and Ingham, 1996; 
St-Jacques et al., 1999; Kindblom et al., 2002). PTHrP promotes the 
proliferation of chondrocytes in the growth plate and their hypertrophy is 
triggered when PTHrP levels fall below a critical threshold. This shows that a 
high PTHrP levels inhibit chondrocyte hypertrophy. The interaction of IHH with 
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PTHrP during chondrocyte proliferation counteracts the inhibitory role of the 
GLI3 repressor in this process (Fig. 8) (Hilton et al., 2005). In particular, 
inactivation of both GLI3 and IHH restores the proliferation defects, disruption 
of PTHrP expression and hypertrophy observed in Ihh deficient limbs. These 
results are in agreement with the proposal that IHH and PTHrP regulate 
chondrocyte proliferation and maturation in a synergistic manner (reviewed by 
Long and Ornitz, 2013). In addition, the functions of FGF signaling, in 
particular FGF receptors Fgfr1 and Fgfr3, in regulating pre-hypertrophic and 
hypertrophic chondrocytes has also been analysed (Peters et al., 1992; Deng 
et al., 1996; Ornitz and Marie, 2002; reviewed by Long and Ornitz, 2013). 
Conditional deletion of Fgfr1 in chondrocytes delays the maturation of 
hypertrophic chondrocytes (Jacob et al., 2006), while deletion of Fgfr3 keeps 
chondrocytes in a proliferative state (Eswarakumar and Schlessinger, 2007). 
Finally, Sox9 keeps the chondrocytes in proliferative state and interfere with 
their progression to hypertrophic states (Dy et al., 2012). 
 
4.6.5 Osteoblast development and endochondral ossification 
The hypertrophic chondrocytes mature and direct the mineralization of the 
surrounding matrix by osteoblasts.  This results in a physiological environment 
that attracts invasion of blood vessels by vascular endothelial growth factors 
(VEGFs) and other signals (reviewed by Kronenberg, 2003). The invading 
chondroclasts and osteoclasts start to degrade the matrix, while the adjacent 
perichondrial cells differentiate into osteoblasts. This results in formation of 
the bone collar that will develop into cortical bone (Mackie et al., 2011). 
Hypertrophic chondrocytes undergo apoptosis and the remaining matrix 
provides the scaffold for osteoblasts and invading blood vessels that 
continues mineralization of the extracellular matrix (ECM) (reviewed by Long 
and Ornitz, 2013).  
Several molecular pathways regulate osteoblast differentiation and functions 
during endochondral ossification. Inactivation of IHH disrupts osteoblast 
differentiation and Runx2 (Runt-related transcription factor 2) activation in the 
perichondrial progenitors, which is essential for osteoblast differentiation 
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(Long et al., 2004). Additional functions of IHH signaling in promoting 
chondrocyte hypertrophy independent of PTHrP have also been evidenced 
(Mak et al., 2008). A recent study showed that IHH impacts on the Col10a1 
promoter via Gli transcriptional regulators or indirectly via the Runx2/Smad 
pathway (Amano et al., 2014). The Osx transcriptional regulator acts 
downstream of Runx2 and BMPs are critical to osteoblast differentiation 
(Nakashima et al., 2002). In particular, threshold levels of BMP2 and BMP4 
are required for the transition from Runx2 to Osterix positive cells 
(Bandyopadhyay et al., 2006).  
Thus, Fig. 9 summarizes all the steps of endochondral ossification: 
 
Fig. 9.  (a) Mesenchymal cells condense and rearrange in orderly manner. (b) Condensed 
cells differentiate into chondrocytes (c). (c) Chondrocytes in the center stop their proliferation 
and become hypertrophic (h). (d) Adjacent perichondrial cells differentiate into osteoblasts, 
forming the bone collar (bc). Apoptosis and mineralization of hypertrophic chondrocytes lead 
to physiological changes, which begin to attract blood vessels. (e) Vascular invasion and 
osteoblasts promote formation of the primary spongiosa (ps). (f) Proliferating chondrocyte 
underline the longitudinal growth. (g) Hypertrophic program in chondrocytes along with 
vascular invasion and osteoblast activity leads to formation of secondary ossification centres 
at the distal ends of the bone rudiment (soc). The growth plates formed are by proliferating 
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columnar chondrocytes (col). The hematopoietic compartment of the bone marrow (hm) 
invades the marrow space along with stromal cells. (Kronenberg, 2003). 
 
4.6.6 Hematopoiesis during endochondral ossification 
The process by which hematopoietic stem cells (HSCs) differentiate and form 
all types of blood cells is called as hematopoiesis. HSCs and Hematopoietic 
cells from fetal liver migrate to the marrow space of endochondral bone via 
the invading blood vessels. In this process, HSCs continuously give rise to 
common myeloid progenitors (CMPs) and common lymphoid progenitors 
(CLPs). CMPs differentiate further to generate erythrocytes, platelets, 
macrophages, neutrophils, eosinophils, basophils and megakaryocytes. CLPs 
differentiate into natural killer cells, T-cell progenitors that would mobilize from 
bone marrow and complete their differentiation in the thymus and B-cell 
progenitors that would complete their program of differentiation in bone 
marrow. Dendritic cells arise both from CMPs and CLPs (Miyamoto et al., 
2002; Iwasaki and Akashi, 2007; Kondo, 2010; reviewed by Weissman and 
Shizuru, 2008). Functional HSCs in bone marrow of mice is observed by 
E17.5 stage and is mainly residing in the endosteal region, at the interphase 
between bone and BM (Christensen et al., 2004). During hematopoiesis, 
HSCs in bone marrow interact with stromal cells and establish the stem cell 
niche and maintain a steady state (Greenbaum et al., 2013; Chan et al., 
2015).  
 
4.7 Guiding MSCs towards endochondral ossification 
During chondrogenic differentiation in vitro, the BM-derived MSCs display 
features of growth plate chondrocytes (Pelttari et al., 2008; Steinert et al., 
2009; Scotti et al., 2010; Caron et al., 2012). However, the hypertrophic 
program in differentiating chondrocytes is triggered in a rather uncontrolled 
manner. In vitro studies using hMSCs, cultured in three-dimensional (3D) 
constructs have been used for directed, step-wise induction of 
chondrogenesis, hypertrophy and finally bone formation (Ichinose et al., 2005; 
Sasaki et al., 2012). These experiments reveal the importance of the 3D 
environment in attempting to mimic in vivo physiological conditions. In 
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addition, endochondral ossification must be paralleled by hematopoiesis to 
form functional bone. Cartilage templates made from human BM-MSCs are 
capable of recapitulating the embryonic process of endochondral ossification 
following their subcutaneous implantation in the immunosuppressed nude 
mouse model (Scotti et al., 2010). As the process involves vascularization, 
endothelial cells were indeed detected in the resulting bony ossicles. In 
addition, osteoclasts were detected, which are key to active matrix 
degradation during endochondral ossification. The importance of MSCs and 
osteoprogenitors in regulating the hematopoietic stem cell niche has also 
been addressed for both human and murine model of endochondral 
ossification (Chan et al., 2009).  Others studies point to the necessity of 
chondrogenic priming of MSCs in vitro to stimulate bone regeneration in vivo 
(Farrell et al., 2011; Van der Stok et al., 2014). Priming MSCs with IL-1β 
(interleukin-1β) in hypertrophic medium prior to implantation results in 
enhanced vascularization and osteoclast activity and enlarged bone marrow 
regions (Scotti et al., 2013). Another study indicates that chondrocytes 
derived from MSCs can revert back to their stromal phenotypes, which 
supports hematopoiesis and homing of hematopoietic stem cells (Serafini et 
al., 2014). 
 
While MSCs can be differentiated into osteoblasts and recapitulate aspects of 
endochondral ossification, the generation of e.g. growing and stable cartilage 
templates to much better mimic bone growth has not been accomplished. 
Fate mapping studies in the mouse begin to provide a deeper understanding 
of functions and fates of mesenchymal progenitor cells in growing bone with 
respect to their osteogenic or chondrogenic lineage contributions. Using Col2-
creER; R26R–tdTomato double transgenic reporter mice in combination with 
a Col1(2.3kb)-GFP allele to mark osteoblastic cells, it was shown that the 
cartilage and perichondrium compartments arise early during embryonic 
development as precursors of the Osterix+ cells (Mizoguchi et al., 2014). After 
birth, these cells give rise to chondrocytes, osteoblasts, osteocytes and 
Cxcl12-expressing stromal cells within the marrow space. Similar results were 
obtained by fate mapping of Sox9–creER positive cells. These results indicate 
that the Sox9 positive osteo-chondrogenic progenitors give rise to 
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chondrocytes, osteoblasts and stromal cells during endochondral bone 
development. These studies are highly relevant to gain insight into the nature 
of the progenitor cells best suited for bone regeneration and generating stable 
cartilage. Very recently, evidence for achieving stable cartilage was obtained 
by CD200+ cells in combination with other surface markers from mice (Chan 
et al., 2015). Based on their emergence with other skeletal stem cells during 
development, these skeletal progenitor cells could be potentially used to 
engineer bone or cartilage by modulating there exposure to morphogenetic 
signals. Interestingly, both mouse and human cells express CD200. These 
findings provide insight into the underlying cellular mechanisms and may aid 
in developing protocols to harness well-characterized mesenchymal and 
skeletal stem/ progenitor cells for cartilage and bone engineering in the long 
term. 
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5. Aims of the thesis 
 
Tissue engineering approaches using MSCs and mesenchymal progenitor 
cells for regenerative therapy have indicated several limitations of MSCs to be 
used for therapeutic purposes. These limitations occur predominantly due to 
heterogeneity in MSC populations, donor-to-donor variations, uncontrolled 
differentiation in vitro and in vivo, and physiological differences between in 
vitro and in vivo functionality of these cells. MSCs from murine model have 
recently gained popularity to address some of these issues. It allows using 
sophisticated genetic tools to visualize cells for fate mapping studies. In 
addition, possibility of using a developmental engineering approach from in 
vivo studies in mice allows to gain insight into the lineage commitment of 
these cells. Recently, PαS cells were identified in mice that fitted best with the 
criteria to define MSCs and were chosen as candidate cells for this study. 
 
Few major aims that were developed for the thesis are as follows: 
1) To characterize in detail the adult PαS cells and its ontogenic analysis 
during mouse development, using standard markers of MSCs. 
2) To refine the existing conditions under which PαS cells could be guided to 
a controlled differentiation into cartilage and other lineages in vitro.  
3) To analyze the in vivo fate of cartilage templates derived from PαS cells 
and its subsets. The key question was to analyse whether the PαS cells and 
its subsets, upon in vivo engraftment, retained stable cartilage phenotype or 
remodeled into a functionalized bone, so as to prove them as a better model 
population of MSCs for engraftment.  
 
Characterization of freshly isolated cells allowed generating a ‘CD signature’ 
of PαS cells. These signatures could be tracked in the cells in culture to 
envisage any differences from endogenous PαS cells, especially with respect 
to their multilineage differentiation potential. Ontogenic analysis allowed to 
track the earliest possible emergence of PαS cells and its subsets during 
mouse development. 
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MSCs, which mainly consist of progenitor populations, may determine their 
lineage commitment very early in development. A refinement of lineage 
differentiation protocol, in particular towards chondrogenic lineage, allows the 
possibility to recapitulate the development processes undergoing in vivo. For 
the thesis, several culture conditions and differentiation conditions were tested 
for PαS cells to improve the quality of cartilage templates generated in vitro. 
Although generating stable cartilage by subcutaneous implantation of PαS 
cells remains challenging, striking differences were observed between the in 
vivo engrafted postnatal subsets of PαS cells and cells isolated prior to birth. 
These results will be described and discussed in detail in this thesis. 
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6. Results 
 
6.1 Isolation, characterization and ontogenic analysis of PαS 
mouse mesenchymal stromal/stem cells 
6.1.1 Mice as a source of mesenchymal stromal/stem cells (MSCs) 
Ever since the therapeutic potential of MSC was realized, efforts have been 
made to isolate and characterize these cells from humans and mice in order 
to explore their potential for cartilage/bone engineering and regenerative 
medicine. Bone marrow aspirates have been one of the predominant sources 
of human MSCs (hMSCs). The classical methods of isolation of hMSCs from 
bone marrow have relied on their adherence to plastic and their fibroblast-like 
morphology (Friedenstein et al., 1970). In culture, MSCs display a so-called 
colony-forming units-fibroblasts (CFU-F) property (Friedenstein et al., 1970) 
and they have the capacity to differentiate into multiple lineages, namely 
chondrocytes, osteocytes and adipocytes. Because of the inherent 
heterogeneity of the adherent hMSCs and the associated variability in cellular 
phenotypes (Gothard et al., 2013; Hagmann et al., 2013), further 
characterization and purification of hMSCs is an essential step for their use in 
therapeutic approaches. Advances were also hampered by difficulties in 
isolating rodent bone-marrow mesenchymal cells. During the past 10 years, 
several surface markers amenable to flow cytometry have been identified that 
are expressed in MSCs. Standard cell surface markers used to identify 
hMSCs include CD146, CD73, CD90, CD29, CD44, CD140b, CD105, CD106 
and CD271. Since none of these markers could identify a homogeneous MSC 
population, a combination of different standard markers is used to purify and 
define different bone-derived MSC populations by fluorescence-activated cell 
sorting (FACS). However, the potential essential roles of these cell surface 
markers in the etiology of hMSCs is not yet well understood. Moreover, 
genetic models that could be used to trace the origin and identify the bona-
fide mesenchymal stem/ early progenitor populations and delineate essential 
developmental pathways involved in determining their functions are not 
available for humans. Therefore, the mouse is an essential animal model to 
 39 
isolate and study mouse MSCs (mMSCs) due to its manifold genetic tools. 
Mouse genetics provides an exciting approach to gain further insight into 
mMSC functions in vivo and for detailed characterization of their pluripotent 
differentiation potential. Several of the standard surface markers are 
expressed both by mouse and human MSCs, such that findings from the 
mouse can be transferred to the study of hMSCs. 
 
6.1.2 Challenges in isolation of mouse MSCs 
Since 1961, when Friedenstein described and coined the term mesenchymal 
stem cells, several methods to isolate MSCs have been described (Simmons 
and Torok-Storb, 1991; Sacchetti et al., 2007, Bianco et al., 2008). Originally, 
hMSCs were isolated due to their capacity to adhere to plastic, whereas the 
non-adherent hematopoietic cells were washed away after few passages. 
Unlike hMSCs in culture, mMSCs isolated using the same procedure were 
contaminated with remaining hematopoietic cells (Phinney et al., 1999; 
Rombouts and Ploemacher, 2003).  Fig. 9 shows mesenchymal cells isolated 
from bone marrow of adult mice (BL6, 8 weeks old), which were kept in 
culture for 4 weeks. During culture, their initial fibroblastic morphology 
changed (Fig. 10A, B) and these cultures still contained a considerable 
fraction of CD45+ hematopoietic cells (Fig. 10C).  
 
 
Fig 10. Plastic-adherent mouse bone marrow (BM) mesenchymal cells are 
contaminated with CD45+ hematopoietic cells. (A) BM cells initially display a typical 
fibroblastic morphology (passage p1). (B) This morphology was changed in later passages 
(p5). (C) Immunofluorescent detection of CD45+ hematopoietic cells (p5). The majority of cells 
are CD45 positive (yellow). Nuclei are detected by Hoechst (blue). Scale bar = 50 µm. (n ≥ 6 
independent BM cultures). 
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Bone-derived mesenchymal cells are located in the endosteum and 
perivascular compartments of the bone marrow (Crisan et al., 2008; Morikawa 
et al. 2009; Mendez-Ferrer et al., 2010; Nakamura et al., 2010). Most of the 
markers reported are expressed by human mesenchymal cells isolated from 
bone marrow aspirates (i.e. the perivascular compartment). Mesenchymal 
cells attached to the endosteum can only be retrieved by protease treatment. 
For this reason, the mesenchymal cells from endosteal compartment have 
only recently been studied in the mouse. This compartment is enriched for 
novel types of mesenchymal cells with multi-lineage differentiation potential 
(Morikawa et al., 2009; Chan et al., 2015). Furthermore, recent in vivo studies 
in mouse models have addressed the functions of different MSC subsets and 
their contributions to cartilage and skeletal lineages and tissue during 
embryonic and postnatal development and tissue homeostasis (Park et al., 
2012; Greenbaum et al., 2013; Mizoguchi et al., 2014; Zhou et al., 2014; Chan 
et al., 2015).  
 
In particular, Sca1 (stem cell antigen 1), a mouse stem cell marker expressed 
in hematopoietic stem cells, endothelial cells and other cell types (Ortega et 
al., 1986) and PDGFRα (platelet derived growth factor-alpha), an early 
mesodermal marker (Takakura et al., 1997), were used together to identify a 
rare MSC population (PαS) in the non-hematopoietic lineage of adult mouse 
(8-11 weeks of age) (Morikawa et al., 2009; Houlihan et al., 2012). This PαS 
MSC population undergoes robust trilineage differentiation and displays the 
highest CFU-F efficiency among the known mouse MSC subsets. 
 
6.1.3 Isolation and characterization of adult PαS mouse MSCs 
PαS cells are present at very low frequency in the adult mouse bones and 
bone marrow (Morikawa et al., 2009). Several reports in the literature have 
established that mesenchymal stromal cells lose their multi-lineage 
differentiation potential upon prolonged expansion in culture. Therefore, we 
have characterized freshly isolated PαS cells with respect to their expression 
of mesenchymal CD markers by FACS analysis to establish a “CD signature” 
that could be tracked during expansion in culture and correlated with their 
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multi-lineage differentiation potential. PαS cells were isolated as described 
(Houlihan et al., 2012) (Fig. 11A). The “lineage population” eliminated by 
FACS from the freshly isolated cells consists of a pool of different cells of 
hematopoietic origin that either express CD45 (marker of hematopoietic cells), 
TER119 (marker of erythroid cells), CD11b (marker of macrophage and 
dendritic cells) or CD31 (marker of endothelial cells). In addition, the CD11b 
and CD31 markers were also included in the lineage marker cocktail to also 
eliminate macrophages and endothelial cells from the analysis of 
mesenchymal cells. Dead cells were gated-out using cell dyes (DAPI) to stain 
the cells and the PDGFRα and Sca1 double positive mesenchymal cells were 
isolated using FACS for analysis and culture. The fibroblast-like morphology 
of PαS cells was observed after 5 days in culture (Fig. 11B). CD146 is an 
important marker expressed by self-renewing osteoprogenitors in human 
bone marrow and constitutes ~6% of the non-hematopoietic cells in mouse 
bones (Sacchetti et al., 2007). However, only ~3.5% of PαS cells express 
CD146 (Fig. 11C). On the other hand, CD106 (vascular cell adhesion protein 
1 or VCAM-1), another marker expressed by hMSCs (Mabuchi et al., 2013), is 
detected in ~90% of PDGFRα cells and by ~20% of all lineage-negative cells 
(Fig. 11D). PDGFRβ, another marker expressed by hMSCs, is expressed in 
~90% of all PαS cells (Fig. 11E). PDGFRα was expressed in ~20% of all Lin- 
cells whereas PDGFRβ was expressed in ~18% of all Lin- cells. Hence, in 
mouse, PDGFRα appears to be a slightly better marker to isolate 
mesenchymal cell populations. In a recently published study (Pinho et al., 
2013), the CD51 surface marker was used together with PDGFRα to 
prospectively identify the human MSCs corresponding to the Nestin+ sphere-
forming mesenchymal stem cells that were identified in mouse (Mendez-
Ferrer et al., 2010; Frenette et al., 2013). Recently, CD51 was shown to be 
co-expressed with CD200 in a rare population of mouse skeletal stem cells 
(mSSCs; Chan et al., 2015). CD51 is expressed by ~95% of the PDGFRα+ 
cell population and more than 90% of the Sca1+ positive cells also express 
CD51 (Fig. 11F), which means that PDGFRα and CD51 marks mostly the 
same cells and both can be used to identify the majority of the PαS cell 
population together with Sca1. Interestingly, FACS gating of the CD51+ cell 
population also shows that PαS and CD200+ cell populations (containing 
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skeletal progenitor cells; (Chan et al., 2015) are largely mutually exclusive 
with an overlap of only ~1% between the two populations (Fig. 11F).  
 
 
Fig. 11. FACS based identification and characterization of PαS cells. (A) 7-
Aminoactinomycin D (7-AAD) cell dye allows electronic gating-out of dead cells. Sequentially, 
non-hematopoietic lineage (Lin-) cells were gated including a gate for single cells (based on 
forward (FSC-A) and side scatter (SSC-A) analysis. Finally, the population of Sca1+PDGFRα+ 
double positive cells are isolated as PαS cells. (B) Representative PαS cells cultured for 3, 6, 
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9 and 12 days. (C) Most PαS cells do not express the CD146 marker. (D) ~20% of all Lin- 
cells and ~90% of all PDGFRα+ cells express the CD106 marker. (E) ~90% of all PαS cells 
express PDGFRβ. (F) CD51 is expressed in ~95% of all PDGFRα+ cells and ~90% of all 
Sca1+ cells. CD200+ cells and PαS cells are mutually exclusive, with a minimal overlap of 
~1%. Numbers in gates represent the percentages of the gated populations. Scale bar = 100 
µm. (n ≥3 independent experiments analyzed). 
 
6.1.4 Comparative analysis of freshly isolated and cultured PαS cells  
To date, a serum-free culture medium able to maintain the stemness of MSCs 
has not been defined. Therefore, the “CD signature” of freshly isolated PαS 
cells was compared with the one of PαS cells cultured for several passages in 
parallel to assessing their stemness in tri-lineage differentiation assays (Figs. 
12, 13).  
 
 
Fig. 12.  FACS analysis of the CD signature of freshly isolated and cultured PαS cells 
using standard markers for MSC populations. (A) PαS cells freshly isolated from adult 
mice (passage p0) analyzed using a panel of standard markers of MSCs: CD90, CD73, 
CD44, CD49e and CD105 (panels from left to right). Note that analysis of the CD90 and 
CD73 markers allows division of PαS cells into 4 distinct subpopulations: q1= CD90+CD73-; 
q2= CD90+CD73+; q3= CD90-CD73-; q4= CD90-CD73+). (B) CD signature of PαS cells at 
passage 2 in culture (p2). The q3 subpopulation disappears in culture. A significant fraction of 
the PαS cell population (52 ± 11%) upregulates CD105 expression. (C) CD signature of PαS 
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cells at passage 5 (p5). At p5, CD105 expression is reduced in comparison to p2 in PαS cells. 
(n ≥3 independent experiments). 
 
Several striking differences in the CD signature profile were revealed between 
freshly isolated PαS cells and cells cultured up to five passages. Most 
importantly, combined analysis of several mesenchymal markers revealed 
that the PαS cell population consists of at least four subpopulations with 
distinct CD signatures (Fig. 12A). The relevant markers are CD90.1 (Thy1), a 
cell surface marker originally identified in thymocytes that is also expressed 
by mesenchymal cells (Reif and Allen, 1963; Haeryfar and Hoskin, 2004; 
Dominici et al., 2006; Maleki et al., 2014) and CD73, which functions in 
extracellular adenosine generation whose expression correlates with 
enhanced chondrogenic potential (Campbell and Pei, 2012). The four PαS 
subpopulations defined by the two markers occur with different frequencies: 
most abundant are PαS+CD90+CD73- (q1: 48.5 ± 4.9%), followed by 
PαS+CD90+CD73+ (q2: 29.8 ± 4.5%), while PαS+CD90-CD73- (q3: 9.5 ± 
3.4%) and PαS+CD90-CD73+ cells (q4: 12.1 ± 4.0%)  are much less abundant 
(Fig. 12A, second panel).  
 
During passaging in culture, the proportion of PαS cells expressing higher 
levels of CD90 and CD73 (CD90+CD73+ double positive subpopulation) 
increased (~29.8% at P0 to ~66% at P5). Concurrently, the frequency of the 
double negative subpopulation of PαS cells (q3) decreased (Fig. 12A, B). In 
addition, CD49e (integrin alpha-5, which is part of the α5β1 integrin complex) 
is expressed by all freshly isolated PαS cells. The expression of CD44 (a cell 
adhesion molecule) increased from 75% in freshly isolated PαS cells to all 
cells in culture. Similarly, the expression CD105 (endoglin), which bind to 
ligands of the TGF-β superfamily (Fonsatti, Altomonte et al. 2003) and marks 
bone derived mesenchymal progenitors (Chan et al., 2015) is also 
upregulated to varying extents in culture (Figs 12A-C).  
 
Most importantly, the altered CD signature in culture correlated with the loss 
of stemness in the tri-lineage differentiation assays. In particular, 
chondrogenic and osteogenic differentiation potential was lost after two 
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passages, while the adipogenic differentiation potential was retained in more 
advanced passages (Fig. 13A-F). Taken together, these results show that the 
CD signature of PαS cells changes significantly when freshly isolated cells are 
cultured, owing to the loss of multi-lineage potential, which may result in 
heterogeneity or trigger differentiation under serum-based cell culture 
conditions. This analysis shows that the stemness potential of PαS cells is 
lost by in vitro expansion under culture conditions normally used to expand 
mesenchymal stromal cells.  
 
 
 
Fig. 13. Tri-lineage differentiation of PαS cells. (A, D) PαS cells from adult mice were 
differentiated in a chondrogenic cocktail for 7 days. Control PαS cells that were plated at high 
density in αMEM+ medium do not initiate chondrogenesis (A). Alcian blue staining shows that 
the PαS cells condense and produce glycosaminoglycans (GAGs) in micromass/high-density 
cultures (D, up to passage p2). (B, E) PαS cells were differentiated in osteogenic medium for 
3 weeks. Alizarin red S stains the calcium deposits produced during osteogenic mineralization 
(E, up to p2), while no osteogenesis is observed in controls (B). (C, F) Adipogenic 
differentiation of PαS cells for 10 days leads to formation of lipid droplets detected by Oil O 
Red (F, up to p6), while no adipogenesis is observed in controls (C). Scale bar = 100 µm. (n≥ 
2 independent experiments). 
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6.1.5 Ontogenic analysis of PαS cells in Sox9-GFP mice revealed their 
appearance during mouse embryonic development  
One of the major limitations to overcome in this study was that PαS cells, 
which are more abundant in the endosteum than in bone marrow, represent a 
very rare population (~10,000 cells per adult mouse; see also (Morikawa et 
al., 2009)). The low numbers of PαS cells in adult mouse precluded in-depth 
analysis and attempts to directed differentiation of MSCs into chondrocytes, 
since such experiments require larger numbers of mesenchymal progenitors. 
Besides, the results shown in Figs 12 and 13 establish that the tri-lineage 
potential of PαS cells is rapidly lost in culture. In order to determine if PαS cell 
might be more abundant at early postnatal stages and/or during embryonic 
and fetal development, an ontogenic analysis was performed using different 
stages of embryonic and adult limbs from mice expressing a Sox9-GFP 
reporter (Chan et al., 2011). The SRY-box containing gene 9 (Sox9) is a 
master regulator of chondrogenesis and is one of the earliest markers 
expressed by osteo-chondrogenic progenitors (Akiyama et al., 2005). The 
enhanced GFP was knocked into the endogenous mouse Sox9 locus such 
that the resulting bi-cistronic allele expresses both the SOX9 and EGFP 
proteins (Chan et al., 2011) (Fig. 14A, B). The GFP-positive cells can be 
easily tracked in the lineage negative populations during FACS isolation of 
PαS cells. When PαS cells were isolated from adult Sox9-GFP reporter mice, 
only a small fraction of these cells (~25%) co-expresses GFP (Fig. 14C). The 
majority of GFP-positive cells segregated with the other mesenchymal cells of 
non-hematopoietic origin. This result indicates that the PαS cells are mainly 
early progenitors not yet committed to either chondrogenic or osteogenic 
fates.  
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Fig. 14. Tracking Sox9-GFP expressing cells using a Sox9-GFP mouse reporter line. (A) 
Scheme showing the insertion of an enhanced GFP linked by IRES sequence (IRES-EGFP-
FRT-Neo-FRT cassette) in the 3’UTR of the Sox9 transcript. Black boxes- exons; solid black 
lines- intronic sequences; open boxes- UTRs (Chan et al., 2011). (B) Mouse embryo at 
embryonic stage E13.5 shows GFP-positive cells in limbs. (C) FACS of freshly isolated PαS 
cells shows that only ~25% of the PαS cell population expresses GFP. GFP-positive cells are 
mainly part of Sca1-PDGFRα- cell population, which contains all strongly positive GFP cells. 
(n≥ 2 independent experiments). 
 
In mouse embryonic limb buds, Sox9+ mesenchymal progenitors are present 
by embryonic days E9.25 - E9.5 (Akiyama et al., 2005). These cells are fated 
to chondrogenic and osteogenic lineage during subsequent limb development. 
Therefore, the Sox9-GFP reporter line allows direct comparison of adult PαS 
cells with embryonic LMPs (Sox9- pool of cells) and osteochondro-progenitors 
(Sox9+ pool of cells). Embryonic limb buds at E11.5 were chosen as first 
developmental stage for ontogenic analysis (Fig. 15A). Cartilage in the 
developing limb is formed between E11.5 and E13.5 and at E12.5 – E13.5, 
genes that mark the onset of osteogenesis start to be expressed. 
Mineralization of osteoblastic cells is already evident by E14.5. Hence, this 
stage was analyzed to study a possible correlation of the appearance of PαS 
cells with fetal bone development. Hematopoietic cells migrate from the fetal 
liver into the forming bone marrow and this process continues from E15.5 until 
2 weeks after birth in mice (see Appendix II) (reviewed by Dzierzak and 
Medvinsky, 2008). By perinatal day E18.5, the HSCs/HPCs have appeared in 
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the long bone marrow (reviewed by Mikkola and Orkin, 2006). Therefore, this 
time point was also chosen to study the abundance of PαS cells in fetal 
bones. As hormones such as estrogen regulate the stem cell niche during 
pregnancy and at birth (Nakada, et al., 2014; reviewed by Heo, et al., 2015), 
long bones isolated from mice at postnatal day 2 (P2) were also included in 
the ontogenic analysis. Further, mice at 2 and 4 weeks of age were included 
as adult mice (Fig. 15A). Since embryonic, fetal and adult mice were analyzed 
by FACS, lineage marker set was expanded to also include EpCAM to 
exclude ectodermal cells lineage, Flk-1 to exclude hemangioblasts (Craft et 
al., 2013), F4/80 to exclude macrophages and Gr-1 to exclude granulocyte as 
these cells are involved in marrow development during endochondral 
ossification (Chan et al., 2009).  
 
FACS analysis of LMPs at E11.5 established that a most (~85%) of these 
cells express PDGFRα and about half of them (~45%) co-express Sox9-GFP 
(Fig. 15A). PαS cells are detected at a very low frequency (~0.9% of all Lin-
negative LMPs), but they do not express the CD90 at E11.5 (Fig. 15 A). 
Interestingly, the appearance of PαS cells precedes the one of cells 
expressing Osterix, a master regulator of osteogenesis (Nakashima et al., 
2002; Hosogane et al., 2010; Mizoguchi et al., 2014)). Analysis of fetal bones 
at E14.5 revealed that the PαS population (~1.5%) now also includes a 
significant fraction of CD90 positive (~25%) and negative cells (~75%), hence 
all 4 subpopulations have emerged (Fig. 15A). At E18.5, the abundance of 
PαS cell populations has increased significantly (~20%) and the maximum 
numbers appear immediately after birth (postnatal day 1-3) as the four PαS 
subpopulations make up to ~30% of all Lin negative cells (Fig. 15A, D). At this 
stage the CD90+ subpopulations (including CD90+CD73- and CD90+CD73+ 
cells) amounts to ~35% of total PαS cells, while the others are CD90- PαS 
cells (including both CD90-CD73- and CD90+CD73+ subpopulations). In adult 
bones, the frequency of PαS population decreases to ~7% at 2 weeks and 
less than 1% at 4 weeks. The CD90+ subpopulations increase to ~60% at 2 
weeks and ~75% at 4 weeks of all PαS cells and was maintained at this high 
proportion in even older mice (Fig. 15A, E).  Our ontogenic analysis also 
revealed that the fraction of the lineage negative cells decreased with 
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advancing prenatal and postnatal age in comparison to all cells isolated from 
limb buds and fetal/compact bones (Fig. 15B). This likely correlates with 
endochondral ossification, vascularization and the progression of bone 
marrow development, which results in increased presence of cells belonging 
to the hematopoietic lineage (Lin) (reviewed by Kronenberg, 2003; Chan et 
al., 2015); in the isolated cells. The fraction of Sox9-positive cells 
(corresponding to osteo-chondroprogenitors, chondroblasts and pre-
hypertrophic chondrocytes) increases up to E12.5 and is maintained up to 2 
weeks after birth, but then declines significantly in older mice (Fig. 15C). 
Maintenance of the Sox9+ cell populations prior to birth correlates with cells 
differentiating into chondrocytes, while the osteoblast-producing cells are 
more prevalent after birth. 
 
Taken together, these results show that CD90- PαS cells are first detected in 
limb buds at E11.5 concurrent with the appearance of the mesenchymal 
condensations that form the long bones and digits (Zeller et al., 2009). The 
CD90+ subpopulations of PαS cells become apparent during endochondral 
ossification of the fetal long bones, the fraction of CD90+ PαS cells gradually 
increases from ~25% (E14.5) to ~75% of all PαS cells in adult mice mouse 
(Fig. 15A, E, data not shown for mice after 4 weeks of age). This change in 
ratio likely reflects the in vivo functions of the four PαS subpopulations, which 
may fulfill specific functions and/or may assume different fates during 
progression of chondrogenic and osteogenic differentiation. 
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Fig. 15. FACS based ontogenic analysis of freshly isolated PαS cells during embryonic 
and fetal development and in adult mice. (A) PαS cells appear at around E11.5 (panels in 
1st row). Maximum numbers of PαS cells were detected perinatally (E18.5) and immediately 
after birth (P2), while their numbers dropped as mice aged (panels in 2nd column). PαS+CD90- 
subpopulations appear early (E11.5), while PαS CD90+ subpopulations arise during fetal 
bone formation (E14.5, ~25%) and become predominant in adults (4 weeks, ~75%; panels in 
3rd column). (B) Graph showing a decrease in relative percentages of lineage negative (Lin-) 
cells from E11.5 onward. (C) The fraction of Sox9+ cells in Lin- cells at the different stages. 
(D) The fraction of PαS cells in lineage negative population from E11.5 onward. (E) Relative 
abundance (in %) of PαS+CD90+ (light gray bars) and PαS+CD90- (dark gray bars) 
subpopulations in the PαS cell fraction from E11.5 onward. (n≥ 3 independent experiments). 
 
6.2 Stemness and multi-lineage differentiation potential of the four 
PαS subpopulations at postnatal day 2 (P2) 
 
6.2.1  CFU-F efficiencies of the four PαS subpopulations 
The maximum number PαS+ cells are detected in limb long bone around 
postnatal day 1-3 (P1-3; see before). Therefore, P2 was chosen to determine 
the CFU-F efficiencies of all four PαS subpopulations (q1-q4) individually in 
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comparison to a pool of PαS cells. Following in vitro expansion for 14 days, 
the CFU-F assay established that the colony forming potential of all four PαS 
subpopulations was robust and no significant differences between the pool 
and the different subpopulations were observed (Fig. 16A, B). 
 
 
Fig. 16. CFU-F assay using PαS cells and the q1-q4 subpopulations isolated from 
postnatal day 2. (A) Representative staining of MSC colonies by toluidine blue. Colonies 
with more than 50 cells were counted after 14 days of culture. (B) Graph showing number of 
colonies formed by PαS cells and the four subpopulations per 1000 freshly isolated cells 
seeded in a 10 cm dish (n= 6 replicates from 3 independent sorting events). 
 
6.2.2: The in vitro osteogenic and adipogenic differentiation potential of 
the four PαS subpopulations 
To determine which of the four subpopulations (q1 – q4) harbors progenitors 
with osteogenic potential, their differentiation was induced in vitro and 
assessed by analyzing the expression of specific markers at the mRNA and 
protein level. Following an initial expansion for 5-7 days until which the CD 
signature of the four subpopulations is maintained in vitro (see Appendix III), 
cells were plated at confluency (20,000 cells per cm2). For controls, cells from 
each subpopulation were plated at same density and cultured in expansion 
medium for the same time. Osteogenic differentiation was induced in a 
medium containing β-glycerophosphate, ascorbic acid, dexamethasone and 
BMP-2, and assessed after 21 days in culture. In order to quantify the relative 
fold change in transcription during the differentiation, the expression levels of 
Osterix (osteoblast marker) and Osteocalcin (mature osteocyte marker) were 
normalized to Ribosomal Protein L19 (Rpl19) following real-time qPCR 
amplification (Fig. 17A, B). In comparison to control cells, Osterix expression 
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is upregulated in all four PαS subpopulations. In particular, its normalized 
levels are highest in differentiated cells of the q3 subpopulation. Also, the 
expression in q4 cells is much higher than in q1 and q2 cells (Fig. 17A). In 
agreement to this, Osteocalcin expression is induced in differentiated q3 and 
q4 cells, whereas it is not expressed in q1/q2 differentiated subpopulations 
and controls. Mineralization during osteogenic differentiation was assessed by 
Alizarin Red S staining, which detects deposited calcium. Among the 4 PαS 
subpopulations, only q3 and q4 cells cultured in osteogenic differentiation 
medium showed mineralized Alizarin Red S positive areas (Fig. 17C).  These 
results were also validated by immunohistochemistry, where Osterix detection 
was much more evident in q3 and q4 subpopulations than q1 and q2 cells and 
controls (Fig. 17D).  
 
Taken together, these results show that the PαS+CD90+ subpopulations 
(q3/q4) are able to undergo osteogenic differentiation in contrast to the two 
PαS-CD90- subpopulations (q1 and q2). 
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Fig. 17. In vitro osteogenic and adipogenic differentiation of PαS subpopulations from 
P2 mice. (A, B) Expression profile of Osterix and Osteocalcin after 21 days of osteogenic 
differentiation in q1-q4 subpopulations (normalized to Rpl19 (ribosomal protein L19) 
expression. (C) Alizarin Red S detects calcium deposition during osteogenesis. Insets 
represent the PαS subpopulations cultured in control medium. Scale bar = 100 µm. (D) 
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Immunodetection of Osterix (red) in q1-q4 subpopulations cultured in osteogenic 
differentiation medium and controls (insets). Nuclei are detected by Hoechst (blue). Scale bar 
= 100 µm. (n= 3 independent experiments). (E, F) Normalized expression profiles of PPAR-γ 
and FABP4 after 5 days of adipogenic differentiation (G) Fluorescent staining using Nile red 
of the q1-q4 subpopulations to detect lipid droplets. Insets represent controls. Nuclei are 
detected by Hoechst (blue). Scale bar = 100 µm. (H) Immunodetection of PPAR-γ (green) in 
q1-q4 subpopulations cultured in adipogenic differentiation medium for 5 days and controls 
(insets). Nuclei are detected by Hoechst (blue). Scale bar = 100 µm. (n= 3 independent 
experiments). 
 
To assess the potential of the four PαS subpopulations to undergo adipogenic 
differentiation, their differentiation was induced. For adipogenic differentiation, 
cells were induced by adding peroxisome proliferator-activated receptor 
gamma (PPAR-γ) ligand and BMP2 in a stepwise manner. For controls, cells 
from each subpopulation were again cultured in expansion medium. After 5 
days of differentiation, the expression of PPAR-γ (marks pre-adipocytes) and 
fatty acid binding protein-4 (FABP4, a marker of adipocytes) were assessed 
by real-time qPCR. In comparison to controls, all four PαS subpopulations 
show increased PPAR-γ and FABP4 expression (Fig. 17E, F). Among the 4 
subpopulations, strongest induction of the pre-adipocyte differentiation marker 
PPAR-γ is seen in differentiating q3 cell subpopulations. FABP4 expression is 
highest in q3 and q4 subpopulations, while levels are much lower in q1 and q2 
subpopulations. The fluorescent dye Nile red was used to reveal lipid droplets 
in vacuoles (Fig. 17G). In agreement with molecular analysis, the 
differentiated q3 and q4 subpopulations contain most lipid droplets. These 
results were also validated by immunodetection of the PPAR-γ protein. Most 
PPAR-γ positive cells are detected in the differentiated q3 and q4 
subpopulations (Fig. 17H). These results show that the PαS+CD90+ 
subpopulations undergo adipogenic differentiation, while the PαS+CD90- 
subpopulations have only low adipogenic potential. 
 
6.2.3 The molecular mechanisms that control the chondrogenic 
differentiation of mouse adult PαS cells 
One of the key aspects of this study was to refine the conditions for directed 
 55 
induction of chondrogenesis and track its progression at different time points 
in adult PαS cells with the aim to use the refined protocol to study 
chondrogenic differentiation of the P2 PαS subpopulations. Previous studies 
have established that TGFβs and BMPs play an important role in determining 
the fate of mesenchymal progenitors by regulating mesenchymal 
condensation and differentiation of chondrocytes. MSCs differentiate into 
chondrocytes in a chondrogenic cocktail that includes these growth factors, 
which is able to induce chondrogenesis with variable success (Pelttari et al., 
2008; Scotti et al., 2010; Solchaga et al., 2011). Based on recent further 
refinements (Schmitt et al., 2003; Karamboulas et al., 2010), we decided to 
add TGFβ (TGFβ1 and TGF-β3) and BMP (BMP2 and BMP4) ligands as 
recombinant proteins to the differentiation medium in order to enhance 
chondrogenesis of adult PαS cells. The differentiation medium is a serum-
reduced medium (to avoid serum-effects on chondrogenic differentiation) that 
is supplemented with ITS+ premix (supplementation that contains insulin, 
human transferrin and selenous acid as essential components of the cell 
culture media), dexamethasone and ascorbic acid. The signaling ligands were 
added in different combinations: for protocol 1/Tp the chondrogenic medium 
contained TGFβs for the first 24 hours and was replaced by BMPs. For 
protocol 2/T+B, TGFβs and BMPs were added together for the entire period of 
chondrogenic differentiation.  
 
In order to assess the efficiency of these chondrogenic differentiation 
conditions, adult PαS cells were expanded for 5-7 days in culture and plated 
at high density/ micromass to induce chondrogenesis in the two different 
chondrogenic media or expansion medium for control purposes. Flow 
cytometry, mRNA expression and immunohistochemistry approaches were 
used to assess the progression of chondrogenic differentiation: 
 
a) Flow cytometry based approach: To track the Sox9-GFP expression, 
adult PαS cells from the Sox9-GFP reporter line were used to study the 
commitment of PαS cells to the osteochondrogenic progenitor and 
chondroblast lineages based on GFP expression. To study the progression of 
cell commitment by flow cytometry, it was important to determine the time 
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frame for in vitro cartilage differentiation. As chondrogenic differentiation is 
initiated by the two chondrogenic differentiation media, the expression of Sca1 
is downregulated over time (Fig. 18A, panels from left to right). However, 
under ‘Tp’ conditions, the downregulation of Sca1 was less prominent in 
comparison to differentiating PαS cells under ‘T+B’ conditions. In particular, 
the majority of PαS cells downregulated the Sca1 expression in T+B 
differentiation medium after 10 days in culture. In contrast, Sca1 expression 
remains and Sox9 is not activated in the controls (Fig. 18A, 1st row, panels 
from left to right and 4th row, panels from left to right). In differentiating PαS 
cells, Sox9 is activated as early as 3 days of chondrogenesis under both 
conditions (Fig. 18A, histogram in 4th row). GFP levels are stable over 
prolonged culture in PαS cells cultured under ‘Tp’ conditions, while PαS cells 
cultured under ‘T+B’ conditions initially upregulate Sox9 expression, but GFP 
levels are reduced again when culture is prolonged  (Fig. 18A, histogram in 4th 
row). The massive deposition of extracellular matrix by the differentiating 
chondrocytes interfered with preparation of single suspension after 10 days of 
culture such that later time points could not be analysed by flow cytometry.  
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Fig. 18. Time-course of chondrogenic differentiation of adult PαS cells in culture.  
(A) Dot plot representation of the flow cytometry analysis of PαS cells isolated from the Sox9-
GFP reporter line in two different chondrogenic differentiation media (Tp, T+B). Control PαS 
cells were kept in expansion medium for the same duration of time. Panels in the first 3 rows 
detect the Sca1 and PDGFRα positive (PαS) cells during the 10 day culture period: control 
condition (1st row), ‘Tp’ conditions (2nd row) and ‘T+B’ conditions (3rd row). Panels in 4th row 
represent the histogram analysis of the Sox9-GFP expression in control versus differentiating 
cells at the different time-points (left to right). (B) RT-qPCR analysis of Sox9 and Col2a 
expression (normalized with of Rpl19 expression). (C) Immunofluorescence analysis of adult 
PαS chondrogenesis (cultured for 5 days under ‘Tp’ conditions) detects SOX9 (red) and COL-
II (green). Control = PαS cells at high density in expansion medium. Nuclei are detected by 
Hoechst (blue). Scale bar = 100 µm. (n= 3 experiments from 3 independent sorting events). 
 
b) Molecular approach: In order to validate the results obtained by flow 
cytometry approaches, Sox9 and Col2a expression, which marks 
osteochondrogenic progenitors and chondrocytes was assessed by RT-qPCR 
over 2 weeks of differentiation (Fig. 18B). Consistent with the results from flow 
cytometric analysis of chondrogenic differentiation, Sox9 expression is 
already induced at the 3rd day using the ‘Tp’ culture conditions, maintained 
over time and followed by robust activation of Col2a. Immunofluorescence to 
detect the SOX9 and type-II collagen (COL-II) proteins after 5 days of 
differentiation confirmed the chondrogenic differentiation of the adult PαS 
cells (Fig. 18C). In ‘T+B’ culture conditions, the initial increase in Sox9 
expression is followed by downregulation after 5 days and the change in 
Col2a expression remained negligible at all time points. This indicates that in 
‘T+B’ culture conditions adult PαS cells does not give rise to stable 
chondrocytes. Importantly, in contrast to Sox9 and Col2a, no Col10a1 
expression was detected in either of the culture conditions (see Appendix IV), 
which indicates that in vitro differentiated chondrocytes derived from adult 
PαS cells do not progress to hypertrophic stages.  
 
Taken together, flow cytometry allows to assess chondrogenic differentiation 
by tracking the Sox9-GFP cells committed as osteo-chondroprogenitors 
during differentiation of PαS cells. This analysis reveals the specific time-
points of chondrogenic differentiation in vitro. Moreover, the expression 
analysis shows that the step-wise implementation of TGFβs and BMPs (‘Tp’ 
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culture conditions) induce robust chondrogenic differentiation of PαS cells into 
chondrocytes. In contrast, adding TGFβs and BMPs simultaneously to the 
culture medium does not induce stable chondrocyte differentiation. The 
presence of the SOX9 and COL-II proteins at day 5 of differentiation under 
‘Tp’ conditions confirmed the robustness of the protocol and faster cartilage 
generation in vitro. Therefore, the step-wise induction of chondrogenesis 
involving a TGFβ priming step (‘Tp’ conditions) was used for all subsequent 
chondrogenic differentiation of MSCs in culture. 
 
6.2.4 In vitro chondrogenic differentiation potential of the four PαS 
subpopulations 
The chondrogenic differentiation potential of the four PαS subpopulations was 
assessed at postnatal day P2. Cells of the four subpopulations were plated at 
high density/ micromass and their differentiation in vitro for 5 days and the 
expression of Sox9 and collagen type-II assessed. For controls, cells from 
each subpopulation were plated at same density and cultured in expansion 
medium. Chondrogenic differentiation was induced in the ‘Tp’ culture 
conditions (stepwise addition of TGFβ and BMP ligands (Fig. 19). Analysis of 
transcript levels showed that Sox9 gene expression was upregulated in all 
subpopulations in comparison to the controls. However, the normalized 
expression levels of Sox9 and Col2a genes are much higher in the 
differentiated q3 and q4 subpopulations in comparison to the q1 and q2 
subpopulations (Fig. 19B). The strongest chondrogenic differentiation is 
observed in q4 subpopulation. The highest levels of Col2a transcripts are 
observed in the differentiated q3 and q4 subpopulations. Immunofluorescence 
analysis confirmed that SOX9 and COL-II protein levels are highest in the 
differentiated q4 subpopulation followed by q3 subpopulation, while much 
lower levels of SOX9 and COL-II are observed in the q1, q2 subpopulations 
and all control populations (Fig. 19C). These results show that the PαS+CD90- 
subpopulations (harboring the q3 and q4 cell) undergo chondrogenic 
differentiation with much higher efficiency than the PαS-CD90- subpopulations 
(harboring the q1 and q2 cells). 
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Fig. 19. In vitro chondrogenic differentiation of the four PαS subpopulations isolated 
from P2 mice. (A) Representative gating by flow cytometry shows isolation of the 4 PαS 
subpopulations. (B) Normalized Sox9 and Col2a transcript levels in q1-q4 subpopulations 
after 5 days of chondrogenic differentiation. Controls are cells cultured in expansion medium 
for the same time. (C) Immunofluorescence detection of SOX9 (red) and COL-II (green) in the 
4 PαS subpopulations after 5 days chondrogenic differentiation. Nuclei are detected by 
Hoechst (blue). Scale bar = 100 µm. Each analysis was performed using n= 3 experiments 
from 3 independent sorting events. 
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6.2.5 The chondrogenic differentiation potential of MSCs isolated from 
mice is robust in 3D scaffold cultures 
It is important to culture MSCs differentiating into chondrocytes in an 
environment that is closer to the native state of the cells, which allows the 
production of their own extracellular matrix in the scaffold. The results 
described indicated that the tri-lineage differentiation potential of PαS+CD90- 
cells (q3 and q4 subpopulations) is significantly higher than the one of 
PαS+CD90+ cells (q1 and q2 subpopulations). In order to assess the 
chondrogenic differentiation of these subpopulations in 3D culture, isolated 
PαS+CD90+, PαS+CD90- and PαS cell populations were expanded for 7 days 
before seeding them in 3D scaffolds. These consisted of type-I collagen 
sponges seeded with 100,000 cells per 4mm diameter of scaffold. These 3D 
culture constructs were induced to undergo chondrogenic differentiation for 
another 7 days using the step-wise ‘Tp’ culture conditions. Controls were 
plated in the same set-up and cultured in expansion medium (no induction of 
chondrogenesis). Histological staining with Safranin O reveals the presence of 
glycosaminoglycans (GAGs) produced during the chondrocyte maturation and 
deposited as extracellular matrix (Fig. 20A). Most GAGs are produced by 
PαS+CD90- cells, followed by PαS+ and PαS+CD90+ cells. The levels of SOX9 
and COL-II proteins (Fig. 20B) are in agreement with the data obtained by 
Safranin-O staining. These results show that the chondrogenic differentiation 
potential of PαS cells and its subpopulations is robust in 3D culture, with the 
chondrogenic differentiation potential being highest in PαS+CD90- cells. 
Hence, the differences in the chondrocyte differentiation potential recapitulate 
the results obtained in two-dimensional high density/ micromass cultures. 
However, this 3D culture analysis also shows that PαS+CD90+ cells (q1 and 
q2 subpopulations) are able to undergo chondrogenic differentiation cartilage 
in contrast to 2D cultures. One possibility is that the q1 and q2 subpopulations 
together are able to trigger chondrogenesis in 3D culture, whereas separately 
they cannot trigger differentiation in 2D culture.  
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Fig. 20. In vitro chondrogenic differentiation of PαS subpopulations in collagen type-I 
sponge matrixes (3D scaffolds). (A) Histological sections stained by Safranin-O reveal the 
GAGs produced during 7 days of chondrogenic differentiation by PαS (upper panels), 
PαS+CD90+ (middle panels) and PαS+CD90- cells (lower panels). No GAGs production was 
observed in control scaffolds. Scale bar = 100 µm. (B) Immunofluorescent detection of SOX9 
(red) and COL-II (green) in PαS (upper panels), PαS+CD90+ (middle panels) and PαS+CD90- 
cells (lower panels) after 7 days of chondrogenic differentiation. Nuclei are stained by Hoechst 
(blue). Scale bar = 100 µm. (n= 2 independent experiments). 
 
These results reveal a very important finding that fully supports the results of 
the ontogenic analysis described in section 6.1.5. The PαS subpopulations 
with better tri-lineage differentiation capacity (q3 and q4) arise early during 
embryonic limb bud development. In addition, the q3 subpopulation is the one 
that most rapidly differentiates/disappears in culture. Another interesting 
finding of the 3D chondrogenic cultures is that PαS+CD90+ cells (q1 and q2 
subpopulations) that performed poorly in 2D chondrogenic differentiation 
assays are able to undergo chondrogenic differentiation in collagen scaffolds.  
 
6.3 Assessment of the in vivo chondrogenic and osteogenic 
potential of PαS cells isolated from postnatal day P2 
Next, we assessed the in vivo differentiation potential of PαS cells and 
subpopulations with respect to generating cartilage and bone tissue via 
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endochondral ossification. The in vivo differentiation potential was assessed 
using subcutaneous implantation of the 3D scaffolds containing differentiated 
cartilage and expanded PαS cells and subpopulations (Fig. 20) in nude mice 
(Scotti et al., 2010).  
 
6.3.1 Remodeling of implants from PαS, PαS+CD90+ and PαS+CD90- cells  
PαS cells, PαS+CD90+ and PαS+CD90- cells differentiated into cartilage for 7 
days in 3D scaffolds were implanted subcutaneously under the skin of nude 
mice together with matched constructs containing undifferentiated cells. Eight 
weeks later, the implants were initially analyzed by Hematoxylin/eosin and 
Safranin-O staining. This analysis showed that bone tissue has formed in the 
cartilage-differentiated constructs derived from PαS and PαS+CD90+ cells 
(Fig. 21A, B). The bony ossicles formed by PαS implants are overall smaller in 
comparison to their PαS+CD90+ counterparts, but bone marrow cells are 
observed in both types. In contrast, only rudimentary bone tissues are seen in 
PαS+CD90- constructs (Fig. 21B). No bony ossicles form in any of the control 
constructs implanted (Fig. 21, insets). These results show that PαS and their 
subpopulations undergo remodeling from cartilage to bone following in vivo 
implantation of the in vitro differentiated 3D scaffolds. Remodeling of cartilage 
into bone is most prominent for PαS+CD90+ cells, while PαS+CD90- cells 
appeared to only partially remodel into bone, suggesting that the two PαS 
subpopulations have a distinct in vivo potentials.  
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Fig. 21. Implants of cartilage templates derived from PαS, PαS+CD90+ and PαS+CD90- 
cells at P2 undergo differential remodeling into bone in vivo. (A, B) Safranin O and 
Hematoxylin/eosin staining on histological sections of PαS (upper panels), PαS+CD90+ 
(middle panels) and PαS+CD90- constructs (lower panels) after 8 weeks of subcutaneous 
engraftment in nude mice. Regions of bony tissue (b) and bone marrow (bm) are indicated. 
Insets show undifferentiated control implants (c). Safranin-O stained sections (A) were 
counterstained by acid fast green to stain the non-collagen sites in the scaffold. Scale bar = 
200 µm. (n= 2 independent implants). 
 
6.3.2 Sox9 remains expressed specifically in implants of PαS+CD90- 
seeded scaffolds after eight weeks  
In PαS and PαS+CD90+ explants that have undergone remodeling of cartilage 
into bone, no cells positive for nuclear SOX9 proteins are detected by 
immunofluorescence within the bony ossicle (Fig. 22). A few SOX9-positive 
cells are detected outside the bony ossicles formed by PαS+CD90+ cells. In 
contrast to PαS and PαS+CD90+ implants, larger regions of SOX9-positive 
cells are detected in the PαS+CD90- implants that have undergone ossification 
to a lesser extent (Fig. 21 and Fig. 22F-F2). The small areas that by histology 
display characteristics of bony tissue were mostly devoid of SOX9-positive 
cells. These data indicate that although PαS and PαS+CD90+ constructs 
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differentiated into cartilage in vitro undergo remodeling upon engraftment, the 
PαS+CD90- constructs tend to retain their cartilage-like features. The 
presence of significant numbers of SOX9 expressing cells with lower levels of 
remodeling into bone is indicative of either partial differentiation of 
chondrocytes into pre-hypertrophic chondrocytes or retention of mesenchymal 
features by PαS+CD90- cells eight weeks after implantation of the 
differentiated cartilage into nude mice. However, no Col-II and Aggrecan 
expression was detected (data not shown).  
 
Fig. 22.  SOX9 expression in the different implants after eight weeks in nude mice  
(A, C, E) undifferentiated control implants. (B, D, F) Immunofluorescent detection of the 
SOX9 protein (red) in the in vivo differentiated (8 weeks) implants of PαS (B), PαS+CD90+ (D) 
and PαS+CD90- (F) constructs. The two enlargements show the SOX9 positive cells in PαS 
(B1 and B2), PαS+CD90+ (D and D2) and PαS+CD90- (F1 and F2) constructs. Abundant 
SOX9-positive cells remain only in the PαS+CD90- constructs after 8 weeks of implantation 
(F1, F2). Nuclei are detected by Hoechst (blue). Scale bars = 500 µm (left panels, low 
magnification).  Scale bars = 100 µm (high magnifications). n≥ 3 independent experiments 
per dataset shown.  
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6.3.3 Development of a bona-fide hematopoietic environment in the bony 
ossicles of the PαS and PαS+CD90+ constructs upon implantation 
Immunofluorescent detection of Osterix antibody (OSX) revealed the 
presence of abundant osteoblasts in sites of bony tissue formation (Fig. 23B, 
with 2 representative insets enlarged as B1, B1’, B2, B2’; and D, with 2 
representative insets enlarged as D1, D1’, D2, D2’). In addition, the forming 
bone tissue is vascularized by recruitment of endothelial cells as 
chondrocytes undergo the pre-hypertrophic to hypertrophic transition and 
ossification is initiated (Fujita et al., 2010; reviewed by Kronenberg, 2003). 
Indeed, OSX-positive osteoblasts were present throughout the bony ossicle in 
close proximity to CD31+ endothelial cells. In contrast, significantly fewer 
OSX+ osteoblasts and no CD31+endothelial cells were detected in PαS+CD90- 
implants (Fig. 23F-F2’). This feature of the PαS+CD90- constructs agrees with 
their retention of more cartilage-like feature after 8 weeks of implantation. The 
lack of endothelial cells suggests that these implants were likely not 
undergoing endochondral ossification at the time of analysis. Finally, only 
cartilage that had formed during the prior in vitro differentiation can be 
remodeled into bone after implantation, as no osteoblasts and endothelial 
cells were detected in control implants (Fig. 23A, C, E).  
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Fig. 23. PαS and PαS+CD90+ constructs remodeled into bone tissue in vivo attract 
endothelial cells. (A, C, E) Control implants. (B, D, F) Immunofluorescence detects OSX –
positive osteoblasts (red) and CD31-positive endothelial cells (green) in implants of PαS (B), 
PαS+CD90+ (D) and PαS+CD90- (F) cells. The enlargements show the presence of 
osteoblasts and endothelial cells in the PαS (B1, B1’, B2 and B2’), PαS+CD90+ (D1, D1’, D2 
and D2’) and PαS+CD90- (F1, F1’, F2 and F2’) subpopulations. Endothelial cells have a 
typical elongated morphology and are always surrounded by the osteoblasts in the marrow 
forming regions. In the PαS+CD90- subpopulation, very few OSX-positive osteoblasts (F2, F2’) 
and no endothelial cells are detected. Nuclei are detected by Hoechst (blue). Scale bars on 
overview images = 500µm.  Scale bars in enlargements =100 µm. (n≥ 3 independent 
experiments).  
 
Histological analysis of the PαS and PαS+CD90+ implants revealed the bony 
ossicles with the enclosed bone marrow. The cells of the bone marrow in 
these implants could arise from HSCs specified as myeloid and lymphoid 
progenitors in the functionalized bone tissue during hematopoiesis. In 
particular, common myeloid progenitors (CMPs) give rise to erythrocytes, 
platelets, macrophages, neutrophils, eosinophils, basophils; whereas common 
lymphoid progenitors (CLPs) gives rise to natural killer cells, T-cell progenitors 
and B-cell progenitors that complete their differentiation program in the bone 
marrow. Dendritic cells are known to arise from both CMPs and CLPs 
(Miyamoto et al., 2002; Iwasaki and Akashi, 2007; Kondo, 2010; reviewed by 
Weissman and Shizuru, 2008). Macrophages present in the developing bone 
marrow are detected by F4/80 (also positive for CD45) in the long bones at 
postnatal day 2 in regions also containing Sca1-positive cells (Fig. 24A-D). 
Analysis of bone ossicles derived from implants of PαS+CD90+ cells shows 
that their bone marrow contains CD45-positive hematopoietic cells (CD45+) 
and F4/80-positive myeloid cells. (Fig. 24E-E1”, E2-E2”). 
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Fig. 24. Macrophages are observed at sites of hematopoiesis in remodeled bony tissue 
derived from the P2 cartilage implants (A-D) Immunofluorescence analysis of the 
distributions of the F4/80 (red), Sca1 (green) and CD45 (cyan) antigens in the bone marrow 
of long bones at postnatal day P2. (E, E1-E1”, E2-E2”) Immunofluorescence analysis of the 
distributions of the F4/80, CD45 and Sca1 antigens in two representative insets from the 
remodeled implants of PαS+CD90+ cells. This analysis reveals the presence of F4/80-positive 
macrophages in the marrow together with CD45 and Sca1-positive cells. Inset in panel E 
shows the undifferentiated control without macrophages. Nuclei are detected by Hoechst 
(blue). Scale bars in left panels = 500µm. Scale bars in right panels = 100µm. (n≥ 2 
independent experiments).  
 
B220, an isoform of CD45, is predominantly expressed by pre and mature B-
cells and in plasmocytoid dendritic cells (Ferrero et al., 2002; Manilay and 
Zouali, 2014). In order to access whether the bone marrow in the bone 
ossicles derived from PαS and PαS+CD90+ cells contained lymphoid 
progenitors, the B220 antibody was used to detect B-cells at the sites of 
hematopoiesis. Indeed, B220-positive B-cells are present in the marrow of the 
bony ossicles in both types of implants (Fig. 25B-B2 and Fig. 25D-D2). In 
contrast, no B220-positive cells are present in implants derived from 
PαS+CD90- cells (Fig. 25F- F2) and controls (Fig. 25A-A2, C-C2 and E-E2). 
Taken together, these results show that the implants derived from PαS and 
PαS+CD90+ cells support hematopoiesis and the development of myeloid and 
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lymphoid cells in the resulting bone ossicles, while this is not the case for 
PαS+CD90- cells. 
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Fig. 25. Implants derived from PαS and PαS+CD90+ cells support B-cell development at 
sites of bone formation. (A, C, E) Controls do not contain B220-positive cells. (B, D, F) 
Sections of bone ossicles derived from PαS cells (B), PαS+CD90+ (D) and PαS+CD90- (F) to 
detect B220-positive B-cells (red fluorescence). Middle and right panels: enlargements to 
show the presence of B220-positive cells. B220-positive cells are absent from implants 
derived from PαS+CD90- cells. Nuclei are detected by Hoechst (blue). Scale bars left panels = 
500µm.  Scale bars right panels = 100µm (n≥ 3 independent experiments). 
 
To determine whether the bone ossicles derived from PαS and PαS+CD90+ 
cells had recruited bona-fide hematopoietic progenitors, the potential 
expression of Sca1 was assessed. Hematopoietic progenitors express Sca1 
and CD45 (Sca1+CD45+) in the lineage negative population, which consists of 
long- and short-term HSCs (Rebel et al., 1996; Ara et al., 2003). In implants 
derived from PαS and PαS+CD90+ cells, clusters of Sca1-positive cells are 
observed at the sites of hematopoiesis in contrast to controls (Fig. 25). Among 
these cells, rare hematopoietic progenitor cells (HPCs) expressing both CD45 
and Sca1 antigens (CD45+Sca1+) are observed (Fig. 26B, B1-B1’, B2-B2’; 
25D, D1-D1’, D2-D2’). In contrast, only few scattered CD45-positive, but no 
CD45+Sca1+ double positive cells are detected in implants derived from 
PαS+CD90- cells (Fig 26F, F1-F1’ and F2-F2’).  
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Fig. 26. Bone ossicles that develop from implants derived from PαS and PαS+CD90+ 
cells contain hematopoietic progenitors. (A, C, E) No CD45 and Sca1 double positive 
HPCs are observed in undifferentiated control implants. (B, D, F) Analysis of implants derived 
form PαS (B), PαS+CD90+ (D) and PαS+CD90- (F) cells reveals CD45 (red) and Sca1 (green) 
positive cells. Solid arrowheads point to regions with HPC cells that co-express CD45 and 
Sca1 (HPCs). Representative regions showing these double positive HPCs are shown in the 
middle and right panels for the PαS (B) and PαS+CD90+ (D) derived implants. In contrast, 
HPCs are absent in remodeled PαS+CD90- cells (panels F). The enlargements show the 
presence of few CD45 single positive cells. Nuclei are detected by Hoechst (blue). Scale bars 
left panel = 500µm.  Scale bars in D1 = 500µm. Scale bar in composites (D1, D1’, F1, F1’, F2, 
F2’) = 100µm. Scale bars in enlarged insets = 20µm. (n≥ 3 independent experiments). 
 
Taken together, these results show that HPCs are present in the bone 
ossicles that had developed from cartilage implants derived from PαS and 
PαS+CD90+ cells isolated at postnatal day P2. The analysis of Osterix and 
CD31 expression showed that remodeling of cartilage implants derived from 
PαS and PαS+CD90+ cells into bone tissue results in vascularization and 
endothelial cell recruitment from the host must be one of the first steps in this 
process. The bone ossicles derived from PαS and PαS+CD90+ cells support 
hematopoiesis resulting in lymphoid and myeloid progenitors. The presence of 
Sca1+CD45+ HPCs at sites of hematopoiesis are indicative of the bone 
ossicles having developed the microenvironment required for hematopoiesis 
within the implant placed ectopically under the skin of a nude mouse. In 
contrast, remodeling of the implants derived from PαS+CD90- cells is much 
more restricted. The continued presence of Sox9+ cells in the remaining areas 
of cartilage suggest that the PαS+CD90- derived implants retain cartilage-like 
features and are likely unable to remodel into bone by endochondral 
ossification. 
 
6.3.4 Analysis of bone ossicles derived from DsRed cells shows that the 
hematopoietic progenitors are host-derived  
As MSCs can differentiate into endothelial cells (Starlinger et al., 2011) and as 
FACS of PαS cells may result in low-level contamination by hematopoietic 
cells, it was essential to determine if the CD31, B220 and CD45 expressing 
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cells are derived from the host (nude mouse) or implant. Therefore, PαS, 
PαS+CD90+ and PαS+CD90- cells were isolated from mice expressing a 
DsRed transgene expressed in all cells under control of a CMV enhancer and 
chicken β-actin promoter (Vintersten et al., 2004). Analysis of bone ossicles 
indeed established that the majority of cells in the implants are DsRed positive 
(Fig. 27B, C). However, CD45-positive endothelial cells and the CD31 and 
B220-positive hematopoietic cells are all not expressing DsRed (Fig. 27D-L). 
These results establish that the endothelial and hematopoietic cells are 
derived from the host nude mice and must invade during the endochondral 
ossification. 
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Fig. 27. Cells of hematopoietic origin are host derived in PαS+CD90- bone ossicles. (A) 
Wild-type cells serve as background control for DsRed fluorescence (B, C) Detection DsRed 
(red) cells and CD45+ (cyan) hematopoietic cells in regions of cartilage (D, E, F) Detection of 
DsRed and CD45 at sites of hematopoiesis. (G, H, I) Detection of DsRed and CD31 positive 
(cyan) endothelial cells at sites of hematopoiesis. (J, K, L) Detection of DsRed and B220-
positive (green) B-cells at sites of hematopoiesis. Nuclei are detected by Hoechst (blue). 
Scale bars on low power image (B) = 500µm. Scale bars on the panels on the left and C = 
50µm. Scale bars for the enlargements from insets = 10µm (n≥ 2 independent experiments). 
 
6.4 Assessment of the in vivo differentiation potential of PαS cells 
isolated from embryonic day E18.5 
From ontogenic studies, it was concluded that CD90 is expressed in PαS cells 
that appear in limb long bones during fetal development (≥E14.5). 
Furthermore, this analysis also showed that the fraction of PαS+CD90+ cells 
among all PαS cells is similar at embryonic day E18.5 and postnatal day P2 in 
mice. Interestingly, the migration of HSCs/HPCs from the fetal liver to their 
definitive location in bone marrow starts at ~E17.5-18.5 and continues until ~2 
weeks postnatally during establishment of bone marrow stem cell niches 
(reviewed by Mikkola and Orkin, 2006). In addition, E18.5 and P2 coincide 
with changes in hormonal regulation during pregnancy and shortly after birth 
(Nakada et al., 2014). Therefore, the migration of HSCs/HPCs and/or the 
hormonal regulation of the developing stem cell niches around birth may also 
influence the PαS cell populations and/or other skeletal progenitor cell-types.  
To assess whether prenatal and postnatal PαS cell populations differ in their 
in vivo differentiation potential, PαS cell populations isolated at E18.5 were 
also analyzed.  
 
6.4.1 Remodeling of implants derived from perinatal PαS cell 
populations (E18.5) 
After 8 weeks of subcutaneous engraftment in nude mice, implants derived 
from prenatal PαS cell populations differentiated in culture prior to 
implantation were analyzed by Safranin-O and H&E staining. This analysis 
reveals their reduced endochondral differentiation potential in comparison to 
implants derived from P2 PαS cell populations (Fig. 28 and see before). A 
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small bone ossicle formed only in implants with differentiated PαS+CD90+ 
cells, while no such ossicles were observed in implants of differentiated PαS 
and PαS+CD90- cells (Fig. 28). Safranin-O staining did not reveal significant 
levels of GAGs in implants after 8 weeks for these latter two cell populations, 
which indicates that these cells did not undergo significant remodeling. 
 
 
Fig. 28. Cartilage templates derived from perinatal (E18.5) PαS+CD90+ cells undergo 
some remodeling to form small bone ossicles, while this is not the case for PαS+CD90- 
and PαS cells at E18.5. (A, B) Safranin-O and H&E staining of histological sections of 
Implants of the three cell populations after 8 weeks of subcutaneous engraftment in nude 
mice. H&E staining reveals a small region of bony tissue (b) in PαS+CD90+ derived implants. 
Insets show the undifferentiated control implants (c). Safranin-O stained histological sections 
were also counterstained by acid fast green to stain non-cartilaginous sites in the scaffold. 
Scale bar =200µm. (n =2 independent implants for each cell-type). 
 
6.4.2 Perinatal PαS cells and their PαS+CD90+ and PαS+CD90- 
subpopulations maintain SOX9 expression to a different extent  
 SOX9 positive cells were observed in the implants in which cells were 
differentiated into cartilage in vitro prior to implantation (Fig. 29B, D and F), 
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while only few scattered cells were detected in control implants that were kept 
undifferentiated in culture (Fig. 29A, C and E). In implants derived from PαS 
and PαS+CD90+ cells, SOX9 positive cells were detected predominantly in 
regions that appear to have remained as cartilage as judged by histological 
assessment, i.e. have not undergone remodeling into bony tissues (Fig. 29B2, 
D2). In cartilage implants derived from PαS+CD90- cells, SOX9 positive cells 
are detected even more (Fig. 29F1, F2). The striking difference between 
these results and the SOX9 expression analysis at postnatal day P2 is that 
many more SOX9-positive cells are detected in implants derived from 
PαS+CD90-, but also PαS and PαS+CD90- cells, at E18.5 than at P2. Hence, 
implants derived from PαS cells and mainly the PαS+CD90- subpopulation 
preserves more cartilage-like features after 8 weeks if the cells are isolated 
just prior to birth (E18.5) rather than shortly after birth (P2). However, 
immunofluorescence analysis did not detect two typical marker proteins for 
chondrocytes, namely COL-II and Aggrecan in implants after 8 weeks in nude 
mice (data not shown). 
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Fig. 29. Perinatal (E18.5) PαS cells maintain SOX9 expression after 8 weeks of 
implantation of cartilage templates into nude mice. (A, C, E) Undifferentiated control 
implants. (B, D, F) Immunofluorescence to detect SOX9-positive cells (red). The enlarged 
insets show the presence or absence of SOX9-positive cells (B1 and B2 in PαS cells; D1 and 
D2 in the PαS+CD90+ subpopulation; F1 and F2 in the PαS+CD90- subpopulation). Nuclei are 
detected by Hoechst (blue). Scale bar in left panels = 100µm. Scale bar in middle panels = 
500µm. Scale bar in right panels = 50µm (n≥ 3 independent experiments). 
 
 
Further molecular analysis reveals that the small bone ossicles that form in 
implants derived from perinatal PαS+CD90+ cells are vascularized, contain 
bone marrow and sites of active hematopoiesis similar to the ossicles derived 
from cells isolated at postnatal day 2 (for details see Appendix VI and data not 
shown). 
 
These results reveal differences in the differentiation potential of fetal (E18.5) 
and early postnatal (P2) PαS cells. The fractions of cells that continue to 
express SOX9 was much higher in embryonic than postnatal MSCs. SOX9 
expressing cells were observed in all implants derived from embryonic PαS, 
PαS+CD90+ and PαS+CD90- cells. The PαS and PαS+CD90+ cells have the 
ability to undergo remodeling and form bone by endochondral ossification. 
Importantly, the ontogenic analysis shows that PαS+CD90- cells arise during 
embryonic development and the emergence of PαS+CD90+ cells coincides 
with the appearance of fetal bone around ~E14.0-14.5 in mouse embryos 
(Coskun et al., 2014). Despite the fact that PαS+CD90- cells are most potent 
with respect to tri-lineage differentiation in culture, the in vivo analysis suggest 
that the different PαS subpopulations may have distinct differentiation 
potentials with respect to endochondral ossification (highest in the 
PαS+CD90+ subpopulation), which is possibly influenced by the 
microenvironment these cells encounter in vivo. 
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7. Discussion 
 
Attempts to identify and characterize “mesenchymal stem cells” have been 
progressing over the last year from both humans and mice, but the ultimate 
proof of the existence of true mesenchymal stem cells is still lacking. In 
contrast to HSCs, which are by now well-established stem cells, the positive 
identification of true mesenchymal stem cells has thus far had several 
limitations. It has proved difficult to establish their stemness at the single cell 
level and their origin and niche in the living organism. That is why the term 
MSC is still used rather for mesenchymal stromal cells than mesenchymal 
stem cells. At the start of my PhD studies, I used classical approaches to 
isolate and expand mouse bone marrow stromal cells (MSCs) and in line with 
other investigators observed significant contamination of the preparation with 
hematopoietic cells. Several improved isolation approaches, which includes 
new markers have been recently developed to enrich MSCs from bone and 
the stromal compartment of bone marrow. But the main aim to use a single, 
homogeneous population of stem/progenitor cells, whose multi-lineage 
potential could be exploited to generate the desired tissues for regenerative 
tissue engineering has not been achieved. For my PhD research, I used the 
PαS cells that were previously identified as a rare MSC-like population in 
mouse bone fractions (Morikawa et al., 2009; Houlihan et al., 2012). PαS cells 
were used as candidate MSC population as based on the in vitro analysis 
they best fitted the criteria used to define MSCs. 
 
7.1 PαS cells are a heterogeneous population 
The previous studies identified adult mouse PαS cells from long bones using 
various surface markers (Morikawa et al., 2009; Houlihan et al., 2012). One of 
the potential problems of working with mouse PαS cells is that the Sca1 
marker cannot be used to identify the human counterparts (Holmes and 
Stanford, 2007). Sca1 is a mouse glycosyl phosphatidylinositol-anchored cell 
surface protein (GPI-AP) belonging to the Lymphocyte antigen 6 (Ly6) gene 
family. A 500kb region of the Ly6 locus was deleted in humans in comparison 
to the orthologous locus in rodents. Notably, the genes flanking the deleted 
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region are conserved between rodents and humans (Holmes and Stanford 
2007). Several human homologs of the Ly6 family do exist, which are closely 
related to the orthologous locus on mouse chromosome 8 (reviewed by 
Bamezai, 1995; Kamiura et al., 1992), but none of these genes are 
orthologous to the rodent Sca1 gene. As the human orthologue of Sca1 has 
not been identified, we considered it important to better define the CD-marker 
signature of mouse PαS cells with the ultimate goal to compare this signature 
with the potentially homologous hMSCs. Both CD51 and PDGFRβ are co-
expressed by the vast majority (≥90%) of all PαS cells, which means that 
these markers for human MSCs can be used interchangeably for prospective 
isolation of MSCs. CD90 and CD73, which are expressed by human MSCs 
(Dominici et al., 2006), are expressed differentially by mouse PαS cells 
resulting in identification of four distinct subpopulations of PαS cells. This 
finding is corroborated by the fact that PαS cells isolated from long bones 
consist of heterogeneous mesenchymal stem and/or progenitor cells. We also 
evidenced additional PαS subpopulations based on the expression analysis of 
other CD markers. CD44, in combination with CD90 also defines four PαS 
subpopulation. However, we predominantly used the CD90 and CD73 
markers to further characterize the PαS cells as CD73 correlates with 
chondrogenic lineage development in studies of human MSCs (Arufe et al., 
2010; Campbell and Pei, 2012; Ode et al., 2013). Furthermore, CD146 is 
expressed by a very small fraction of PαS cells, which underscores the 
differences of these cells from self-renewing osteoprogenitors in the human 
bone marrow (Sacchetti et al., 2007). We also show that the vast majority of 
PαS cells do not express CD200 (only ~1% co-expressing cells), which was 
recently used to identify a skeletal stem cell population (Chan et al., 2015). 
These data also indicate that the PαS and CD200 populations have distinct 
developmental origins. Interestingly, PαS cells up-regulate CD105 during 
early passages in culture. This marker has been used to isolate human and 
also mouse MSCs and CD105 expression has been correlated with increased 
osteogenic potential (Chan et al., 2009). In addition CD105 is implicated in 
angiogenesis (Li et al., 1999; Duff et al., 2003) by mediating the chemokine 
response in endothelial cells and stimulating their migration (Young et al., 
2012). The involvement of CD105 in angiogenesis is in agreement with the 
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increased osteogenic potential of mouse MSCs expressing this marker. In 
particular, PαS cells are able to undergo osteogenic differentiation only during 
early passages in culture, when CD105 expression is upregulated in most 
cells. However, it is important to mention that the observed difference in CD 
signature could be a consequence of the mechanical stress during isolation 
and/or due to removing the PαS cells from their in vivo niche, which could 
result in phenotypic variations within the isolated PαS cell population. 
Nonetheless, these phenotypic differences underscore the complexity of PαS 
cells and MSCs in mice and humans that may reflect differences in their cell 
fates and/or differentiation status. Indeed, the changes in the CD signature of 
PαS cells observed during prolonged culture also affect their multi-lineage 
differentiation potential. The chondrogenic and osteogenic differentiation 
potential is reduced upon prolonged culture, while the adipogenic 
differentiation persisted in these cells. These observations are consistent with 
previously published results (Mabuchi et al., 2013) and corroborate the notion 
that MSCs in serum-based cultures commit to specific lineage(s). The 
increased adipogenic potential at higher passages correlates with the fact that 
during aging MSCs contribute progressively more to adipogenesis in the bone 
marrow (Zhou et al., 2014). Moreover, my analysis showed that the 
PαS+CD90-CD73- subpopulation (q3), which is the rarest and possibly most 
immature of the four subpopulations, disappears first when PαS cells are 
expanded in culture. Either the q3 subpopulation gets eliminated by cell death 
or, if these cells would represent the most immature and stem cell like cells, 
they could give rise to more differentiated cells in culture (thereby contributing 
e.g. to the other 3 subpopulations as q1: PαS+CD90+CD73-, q2: 
PαS+CD90+CD73+ or q4: PαS+CD90-CD73+). BrdU incorporation showed that 
q3 subpopulation proliferates most in culture, which indicates that these cells 
survive and expand rapidly (see Appendix I). This rapid proliferation at the 
expense of ‘stemness’ in culture could explain the observed changes with 
respect to the tri-lineage differentiation potential. Currently, we attempt to 
establish culture conditions that will allow more long-term expansion of PαS 
cells without them undergoing lineage commitment using different 
combinations of signaling molecules known to maintain progenitor/stem cells 
in a proliferative and undifferentiated state.  
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7.2 PαS cells arise around embryonic day E11.5 and increase in 
numbers during perinatal development 
The loss of multi-lineage potential of PαS cells during late passages 
precluded their expansion in culture for more than a few days. Besides, in 
adult mice, PαS cells are rather a rare population in long bones, which poses 
another bottleneck in scaling of experiments. This observation, together with 
the aim to identify the time point when PαS cells arise during embryonic/fetal 
development prompted an ontogenic analysis. Using the Sox9-GFP reporter 
line, we were able to show that PαS cells arise in parallel to specification of 
the Sox9-positive osteo-chondroprogenitors (OCPs) in mouse limb buds. The 
analysis revealed PαS cells in limb buds at E11.5, which coincides with the 
onset of digit condensation and chondrogenic differentiation in the distal limb 
bud mesenchyme (reviewed by Zeller et al. 2009). At this stage the fraction of 
PαS cells is very low and about half of them also express Sox9 indicating that 
this PαS subpopulation is likely specified as OCPs. These results indicate that 
PαS cells contribute to embryonic limb bud development. Interestingly, these 
early PαS cells neither express CD90 nor CD73, i.e. likely correspond to the 
rare q3 subpopulation detected in adult long bones. This supports the 
hypothesis that the q3 subpopulation is first and likely most immature of the 
PαS subpopulations. CD90 is activated only at later stages, as PαS+CD90+ 
cells are identified only at embryonic day E14.5, which coincides with 
mineralization of the extracellular matrix (ECM) by osteoblastic cells 
(Mizoguchi et al., 2014). Therefore, the PαS+CD90+ subpopulation (~25% of 
all PαS cells) may be functionally required for osteogenesis during skeletal 
development as has been proposed by previous studies in MSCs (Chung et 
al., 2013, Yamamoto et al., 2014). Unexpectedly, PαS cells are becoming 
much more abundant by E18.5 and their numbers increased until postnatal 
day P2. It is important to note that the migration of HSCs/HPCs from fetal liver 
to bone marrow starts at E18.5, which results in establishment of the stem cell 
niche in the bone marrow. Several studies provide evidence for an interaction 
of MSCs and HSCs/HPCs in formation of the stem cell niche in the bone 
marrow (Chan et al., 2009; Mendez-Ferrer et al., 2010; Greenbaum et al., 
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2013). The increase in PαS cells may provide a suitable microenvironment for 
HSCs/HPCs during the niche formation in the fetal bone. Of note, the above 
studies also highlighted that the interactions of stromal populations/MSCs with 
hematopoietic progenitors helps to retain the HSCs/HPCs in the bone marrow 
niche. These activities are most prominent during endochondral ossification 
as vascularization and the development of sinusoids in the marrow 
progresses.  
 
As fetal development progresses, osteogenesis becomes dominant over 
chondrogenesis in limbs. Interestingly, comparative ontogenic analysis of PαS 
cells at E18.5 and P2 revealed an increase in the fraction of PαS+CD90+ cells. 
Taken together, these observations suggest that the two subsets of PαS cells 
might have been assigned different fates, whereby the PαS+CD90+ cells could 
contribute to osteogenesis, while the PαS+CD90- cells retain chondrogenic 
potential. Other skeletal progenitors have also been shown to contribute either 
to chondrogenic or to osteogenic lineages (Chan et al., 2009; Park et al., 
2012; Mizoguchi et al., 2014).  Two weeks after birth, a striking drop in the 
number of PαS cells isolated from long bones bone is observed. This 
decrease in PαS cells is paralleled by an increase of the PαS+CD90+ 
subpopulation up to ~75% of total PαS cells. This continuous increase in 
PαS+CD90+ subpopulation may correlate to the fact that bone growth and 
ossification increases and dominates over chondrogenesis in development.  
 
These studies point to the importance of studying the fates of the different 
PαS subpopulations in situ during embryonic and fetal long bone development 
in more detail. However, Sca1 not only marks PαS cells but also HSCs and 
endothelial cells in the bone marrow (Luna et al., 2004; Bradfute et al., 2005), 
which precluded a single cell analysis by immunofluorescence to identify PαS 
cells in their bone marrow niche. Therefore, fate-mapping studies using more 
sophisticated approaches are needed to provide insights into the locations 
and possible functions of the PαS cells during cartilage and bone 
development. 
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7.3 Tri-lineage differentiation potential of the four PαS 
subpopulations 
The  “MSC characteristics” were inherent in all subpopulations of PαS cells 
from postnatal P2 mice. However, the trilineage differentiation could be 
induced much more efficiently in the q3 and q4 subpopulations (PαS+CD90- 
subset), compared to q1 and q2 subpopulations (PαS+CD90+ subset), which 
may correlate to higher stemness potential in this subset. Interestingly, 
induction of osteogenic differentiation in P2 PαS subpopulations was possible 
only after adding BMP4 to the osteogenic cocktail, as against adult PαS cells 
that do not require BMPs for osteogenic differential, was striking. BMPs are 
important mediators of osteogenesis during skeletal development. In vitro and 
genetic analysis has revealed the distinct functions of BMP ligands BMP2, 
BMP4 and BMP7 (Bandyopadhyay et al., 2006). In this study, it was shown 
that absence of BMP2 and BMP4 causes severe limb deformation due to 
impairment in the development of bony tissue. Thus, need of BMPs to trigger 
in vitro osteogenic differentiation in P2 PαS subpopulations is in agreement 
with its distinct role in regulating osteogenesis. BMPs and their receptors are 
known to be already expressed in early embryonic stages and regulate digit 
condensation. During mouse limb bud development, antagonists of BMP 
signaling, such as Gremlin 1 and Noggin modulate BMP activity in spatio-
temporally controlled manner (Merino et al., 1999; Nifuji and Noda, 1999; 
Zuniga; et al., 1999; Ohyama et al., 2001; Wijgerde et al., 2005). In addition, it 
has been shown that TGFβs are secreted by the pre-chondrogenic 
mesenchyme and seem to determine the chondrogenic fates of mesenchymal 
cells during mouse limb bud development, (Lorda-Diez et al. 2009; 
Karamboulas et al., 2010). TGFβs and BMPs are both required for inducing 
chondrogenic differentiation of MSCs. I was able to show that this process is 
more efficient if adult PαS cells are first primed with TGFβs and subsequently 
treated with BMPs to differentiate into chondrocytes. In fact, time-course 
analysis of chondrogenic differentiation of adult PαS cells showed an early 
commitment to the osteo-chondrogenic lineage by upregulation of Sox9 
expression, followed by robust differentiation into chondrocytes as revealed 
by sustained upregulation of Col2a1 expression. On the other hand, a 
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simultaneous exposure of PαS cells to both TGFβs and BMPs had an 
opposing effect as observed in previous studies (Karamboulas et al., 2010). 
PαS cells treated sequentially with TGFβs and BMPs generated stable 
cartilage that did not undergo hypertrophy, which highlights the effectiveness 
of PαS cells to generate cartilage in contrast to the MSC populations used in 
other studies (Tian et al., 2007; Hui et al., 2008; Kim and Im, 2009). I was able 
to show that the q3/q4 PαS subpopulation display the best chondrogenic 
potential both in 2D and 3D culture systems and also produce significantly 
more ECM than the q1 and q2 subpopulations. Together with tri-lineage 
differentiation analysis, these results showed that the PαS+CD90- 
subpopulation (q3/q4) has a better multi-lineage differentiation potential than 
the PαS+CD90+ subpopulation (q1/q2). 
 
7.4 Differential bone remodeling potential of PαS subpopulations 
My analysis showed that the cartilage templates derived from PαS and 
PαS+CD90+ but not PαS+CD90- cells are efficiently remodeled into bone. This 
highlights the differences in the in vivo differentiation potential of these two 
main subpopulations of PαS cells. The efficient remodeling of these cartilage 
templates into bone suggest that the factors required to form hypertrophic 
cartilage and bone could be provided by blood vessels at the ectopic site 
during the process of vascularization, as no hypertrophic chondrocytes were 
seen by in vitro differentiation. Further analysis shows that remodeling had 
occurred to varying extents in all implants, but the PαS+CD90- subpopulation 
retained its “cartilage-like” phenotype or a pre-chondrogenic status to a much 
larger extent than PαS and PαS+CD90+ cells. These results also suggested 
that while PαS+CD90- subset may have the capability to generate more stable 
cartilage in vivo, possibly due to the fact that the cells are not receptive to 
paracrine signals that induce angiogenesis and endochondral ossification, 
which results in maintenance of cartilage-like features following implantation. 
Recently, antagonizing VEGF signaling has been shown to significantly 
promote cartilage tissue generation in vivo from skeletal stem cells in mice 
(mSSCs; Chan et al., 2015).  In contrast, implantation of mSSCs without 
blocking the VEGF pathway resulted in differentiation towards the 
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endochondral route. In another study, a subpopulation of Flk-PDGFRα+ 
mouse ESCs was used to generate chondrogenic mesoderm (Craft et al., 
2013). Upon exposure of these cells to BMP and FGFs resulted in formation 
of hypertrophic chondrocytes. In contrast, exposure to GDF5 in combination 
with blocking the Hedgehog and BMP signaling pathways resulted in 
chondrocytes with features of articular cartilage (Craft et al., 2013). In 
addition, human ES and pluripotent cells (hESC and hPCs) have been 
differentiated into to stable cartilage, by exposing them first to BMP4 and 
FGFs together with other factors and subsequently to TGFβ3 in a temporally 
controlled manner (Craft et al., 2015). Hence, similar pathways might be 
required to induce chondrogenic differentiation of both ESCs and MSCs, 
which suggest that they might also play a role in determining PαS cells to 
generate stable cartilage. 
 
7.5 PαS and PαS+CD90+ cartilage implants promote host-derived 
hematopoiesis during bone marrow formation 
Angiogenesis, which is initiated with formation of the pre-hypertrophic 
cartilage, also results in recruitment of hematopoietic cells to the forming bone 
marrow together with several mesenchymal stromal populations. During 
endochondral ossification, the hypertrophic chondrocytes produce 
extracellular matrix and secrete angiogenic molecules like VEGF and 
transferrin, which stimulate endothelial cell migration towards the hypertrophic 
cartilage (Gerber et al. 1999; Carlevaro et al., 2000). Osteoclasts eliminate 
the apoptotic hypertrophic chondrocytes and the void is filled by osteoblasts. 
In mouse, fate-mapping studies have shown that bone marrow development 
involves complex interactions among several stromal cell populations such as 
Nestin-, CAR-, LepR-, and Cxcl12- positive cells (Mendez-Ferrer et al., 2010; 
Greenbaum et al., 2013; Zhou et al., 2014). In addition, different cells 
committed to osteogenic lineage such as Mx1- and Osterix- positive cells and 
Gremlin1-expressing osteochondroreticular (OCR) stem cells contribute to 
osteoblast formation during endochondral ossification (Park et al., 2012; 
Mizoguchi et al., 2014; Worthley et al., 2015). These cells in the bone marrow 
stroma express HSC maintenance factors and function in the stem cell niche 
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that regulates and maintains HSCs in the bone marrow. Indeed, the process 
of endochondral ossification has been linked to development of the 
hematopoietic stem cell niche (Chan et al., 2009). 
 
As Osterix-positive osteoblasts are detected in the remodeled bone tissue 
formed by PαS and PαS+CD90+ derived cartilage implants, they should 
function to attract endothelial cells in order to continue towards endochondral 
route (my results and Fujita et al., 2010). Indeed, I was able to show that 
CD31-positive endothelial cells expressing CD31 are present in the bone 
ossicle, which indicates that vascular invasion had occurred. By genetic 
marking with DsRed, I was able to show that the endothelial cells are host-
derived, but this only occurred in the cartilage implants that underwent 
significant remodeling of cartilage into bone. 
 
Another important step during hematopoiesis in the developing bone marrow 
is the migration and differentiation of common myeloid progenitors (CMP) and 
common lymphoid progenitors (CLP) due to lineage-specific differentiation of 
HSCs. Host-derived macrophages, which represent one of the differentiated 
cell-types derived form CMPs, were abundantly detected in the remodeled 
bone formed by PαS+CD90+ derived cartilage templates. Moreover, the 
presence of host-derived B-cells and precursors confirmed the establishment 
of lymphoid lineages within the remodeled bone. As no such host-derived 
cells were detected in the poorly or not remodeled cartilage templates derived 
from PαS+CD90- cells, one can conclude that development of a proper 
hematopoietic environment depends on the PαS+CD90+ subpopulation. A 
recent study has shown that conditional deletion of osteoprogenitors results in 
reduced numbers of B-lymphoid progenitors (Greenbaum et al., 2013), which 
may explain their absence from PαS+CD90- derived implants that mostly lack 
osteoblasts. Most importantly, my studies show that PαS+CD90+ derived 
implants provide an environment supportive of initiating HSCs/HPCs niche 
formation during endochondral ossification. In fact, I was able to detect few 
CD45+Sca1+ double positive cells, which represent rare hematopoietic 
progenitor cells (HPCs) within bony ossicles formed by PαS and PαS+CD90+ 
derived implants. As expected, these hematopoietic progenitors are also host-
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derived, which confirms that the fully functional hematopoiesis is entirely host-
derived. Hematopoiesis is a continuous process during bone development 
and maintenance of hematopoietic cells as a consequence of reconstituting a 
hematopoietic microenvironment by stromal populations within an ossicle 
model has been shown before (Song et al., 2010), but it has not been shown 
that this can be achieved by the PαS+CD90+ subpopulation of PαS cells. 
 
Taken together, these findings also suggested striking differences between 
the in vitro and in vivo functions of PαS cells and their subpopulations. While 
“stem” like features in terms of multipotency are more prominent in the 
PαS+CD90- subpopulation during in vitro differentiation, the remodeling by 
endochondral ossification that is supportive for host-derived hematopoiesis is 
a dominant feature of the cartilage implants derived from PαS+CD90+ cells in 
vivo. Such differences in the in vitro and in vivo properties of MSCs have been 
observed before and my results indicate that the complex in vivo roles of 
MSCs may be mediated by specific subpopulations. Moreover, these 
subpopulations may interact in a differential functional manner with 
hematopoietic cells and other stromal components. Furthermore, the 
PαS+CD90+ derived cartilage template, which remodels efficiently into bone 
and attract host-derived hematopoiesis, correlates well with the previously 
observed role of CD90 in enhancing osteogenesis (Chung et al., 2013; 
Yamamoto et al., 2014). In agreement, PαS+CD90+ cells emerge later than 
PαS+CD90- cells during mouse embryonic limb buds development. The fact 
that PαS+CD90- cells are already present at stages during which cartilage 
formation is pre-dominant may explain why these cells retain their cartilage-
like phenotypes better upon engraftment in vivo than PαS+CD90+ cells, which 
remodel efficiently. Hence, correlating the ontogenic appearance of these 
different cell populations with their phenotype following engraftment of 
cartilage templates appears to provide insights into their normal roles during 
endochondral ossification and in attracting endothelial and hematopoietic 
stem cells. 
 
In addition, cartilage templates derived from E18.5 PαS cells, i.e. isolated 
from mouse fetuses prior to birth has less potential to undergo endochondral 
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ossification. Consistent with the observation in the cells from P2 mice, the 
prenatal PαS+CD90- subset appeared to play major role in chondrogenesis, 
while the fate choice of PαS+CD90+ subset towards endochondral route could 
have just been started in prenatal stages.  
 
7.6. Scheme describing the origin of the PαS subpopulations and 
their potential different fates during limb skeletal development 
The results I have obtained during my PhD research can be summarized in a 
scheme that shows development of PαS cells, emergence of the most 
relevant subpopulations and their eventual fates during endochondral 
ossification (Fig. 30A). PαS cells arise from the pool of Sox9- and Sox9+ limb 
bud mesenchymal progenitors around embryonic day E11.0. PαS cells 
express CD73 early in development, followed by the activation of CD90 
expression in a fraction of them, which allows discrimination of two major 
subpopulations at the time the endochondral ossification of the limb skeletal 
bones advances (~E14.5: PαS+CD90+ make up ~25% and PαS+CD90- cells 
~75% of all PαS cells). Following the transition from embryonic to fetal 
development in mice at ~E14.5, HSCs begin to migrate from the fetal liver to 
the developing bone marrow and hematopoiesis is initiated. Together with 
angiogenesis, these events may influence the in vivo choices of PαS cells, 
which coincide with a significant burst in proliferation of both subpopulations 
that are most abundant just at the time of birth. While endochondral 
ossification leads to extensive hematopoiesis, late fetal, i.e. perinatal 
development is also influenced by changes in hormonal regulation, which may 
also affect the differentiation potential of PαS cells, in particular their 
osteogenic and chondrogenic differentiation potential. After birth, 
osteogenesis becomes dominant over chondrogenesis and we observe a 
significant drop in numbers of PαS cells, while the PαS+CD90+ subpopulation 
becomes predominant (making up ~75% of all PαS cells). 
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Fig. 30. Scheme showing the ontogenic development of PαS cells and possible 
regulators of the two main subpopulations during endochondral ossification. 
(A) Mouse limb bud at ~E10.5-E11.0. PαS+CD73-CD90- cells are first detected. CD73 is 
activated prior to CD90. Chondrogenesis (Chondro) lead to pre-hypertrophic (Pre-Hyp) and 
hypertrophic (Hyp) stages. By E14.5, the PαS+CD90+ and PαS+CD90- subpopulations are 
present in the developing fetal bones. Pre-hypertrophic and hypertrophic stages lead to bone 
(B) formation concurrent with migration of HSCs/HPCs from the fetal liver to the developing 
bone marrow stroma (S). Cartilage (C) remains in the epiphyseal region of the developing 
long bones. From ~E18.5 to P2, PαS cells are abundant and bone formation is regulated by 
hormonal changes during birth. Osteogenesis (bold) is pre-dominant over chondrogenesis 
(grey) from early postnatal to adult stages, which is paralleled by a significant drop in PαS 
cells (with PαS+CD90+ cells being the most prominent subpopulation). (B) Scheme shows the 
mechanism by which PαS+CD90+ cells initiate endochondral ossification under the influence 
of unknown determinants (in red). PαS+CD90- cells rather retain cartilage-like features, which 
may depend on antagonists of angiogenesis and other unknown determinants. 
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Thus, identifying and studying the morpho-regulatory signals and 
determinants is a key step to understand the in vivo specification and 
functions of the different PαS subpopulations. Treating mice with specific 
angiogenic antagonists, for example, could be an interesting approach to 
study the specific differentiation and functions of PαS+CD90- cells (Fig. 30B). 
Several studies that have shown the interactions between HSCs and MSCs, 
including the stromal cells in bone marrow and osteoprogenitors regulate the 
activity of the stem cell niche (Mendez-Ferrer et al., 2010; Greenbaum et al., 
2013; Mizoguchi et al., 2014). Therefore it will be important to explore if these 
interactions also regulate the fate choices of PαS cells. Besides, hormonal 
regulation of fate determination and functions of MSCs at the time of birth 
cannot be ruled out. Estrogen (E2), for example, regulates the cell cycle 
activity of HSCs in the developing bone marrow (Nakada et al., 2014; 
reviewed by Heo et al., 2015). In summary, while my study has identified the 
developmental profile, in vitro multi-lineage and in vivo endochondral 
differentiation potential of the different PαS subpopulations, it need to be 
determined which molecular signals and hormone receptors regulate the fate 
choice of the different PαS subpopulations and their potential usefulness as a 
developmental paradigm for cartilage and bone engineering.  
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8. Conclusions and Outlook 
 
The major aims of this thesis were to characterize the mouse PαS cells as 
MSC cells for models of chondrogenic differentiation in vitro by mimicking the 
molecular signals that are active in vivo. Moreover, in vivo functionality of the 
cartilage templates generated from PαS cells and its subsets were assessed. 
My study also contributes to a better understanding of developmental origin of 
mouse MSCs, in particular the four newly identified PαS subpopulations. 
Ontogenic analysis of limb bud mesenchymal cells and developing long bones 
revealed the sequential emergence of the two main subsets of PαS cells 
(PαS+CD90+ and PαS+CD90- cells) and provided evidence for their distinct 
chondrogenic and osteogenic differentiation potential during progression of 
limb skeletal development. Using flow cytometry, molecular analysis and 
immunohistochemistry based approaches allowed me to determine the tri-
lineage potential of the different PαS subpopulations in culture. This showed 
that the in vitro tri-lineage differentiation potential of PαS+CD90-CD73- and 
PαS+CD90-CD73+ subpopulations is much higher in comparison to the 
PαS+CD90+CD73- and PαS+CD90+CD73+ subpopulations. By mimicking the 
molecular pathways that control chondrogenesis in vivo, it was possible to 
generate robust cartilage template in an efficient manner in vitro.  
 
Engraftment of cartilage templates into nude mice revealed striking 
differences between bone-forming potential of the two main PαS 
subpopulations. PαS+CD90+ cell derived cartilage implants display features 
resembling growth plate-like cartilage and are able to remodel into bone 
undergoing endochondral ossification. Interestingly, the resulting bone 
ossicles are vascularized and their sites of active hematopoiesis are both a 
consequence of recruiting host-derived endothelial and hematopoietic 
stem/progenitor cells. In contrast, cartilage implants derived from PαS+CD90- 
cells are only partially remodeled, fails to initiate endochondral ossification 
process and hematopoiesis; and the majority of cells in the implant continue 
to express the Sox9 transcription factor, normally marking osteo-chondrogenic 
progenitors and early chondrocytes. 
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These differences were even exaggerated upon implantation of cartilage 
templates derived from PαS cells from prenatal stage. These observations 
support the hypothesis that was suggested by my ontogenic studies, namely 
that the differentiation potential of implants derived from PαS cells likely mimic 
their normal in vivo potential, which changes during progression of limb bud 
and skeletal bone development. Therefore, it would be most interesting and 
telling to use genetic fate-mapping approaches to track PαS cells in vivo 
during development and combine this approach with manipulation of the 
pathways that control angiogenesis to see if the PαS cells and/or specific 
subpopulations can generate stable cartilage in vivo. 
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9. Materials and Methods 
 
9.1 Mice husbandry and animal experimentation 
9.1.1 Ethics statement 
All experiments with mice were performed in strict accordance with Swiss law, 
the 3R principles and the Basel Declaration. It includes licensing for animal 
experimentation through completion of the LTK-1 course and fulfillment of the 
yearly continuing animal education courses. The severity of experiments with 
mice is classified as grade 0 (implying minimal suffering) for most experiments 
with exception of the engraftment in nude mice (grade 2). 
 
9.1.2 Mouse strains 
For this study, the following mouse strains were used: 
C57BL/6 (wild type), NMRI (wild type), Sox9-GFP reporter strain (Chan et al. 
2011), CMV-Cre transgenic strain (Schwenk et al., 1995), β-Actin-GFP 
transgenic strain (Okabe et al., 1997), CD-1 nude mice (Charles River 
Laboratories).  All mouse strains were bred in the in-house mice facility and 
the last phalange were cut within the first 10 days postnatally to genotype and 
mark the mice. CD-1 nude mice were kept at the Department of Research at 
Universitätspital Basel and the engraftments were done by the group of Prof. 
Ivan Martin. 
 
9.2 Cell preparation and culture 
Cells were grown in their respective media at 370C and with 5% CO2, under 
normal oxygen and humidity conditions in sterile tissue culture incubators. 
 
Cell preparation buffer 
DPBS: Dulbecco’s Phosphate Buffered-saline, pH 7.4 (Gibco #14190-94) 
HBSS: Hank’s balanced salt solution (Gibco #14175-053) 
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HBSS+: 2% FBS Hyclone (Thermo fisher Scientific #1030-9433), 10 mM 
HEPES (Gibco #15630-056) and Penicillin-streptomycin (1000 units, Gibco 
#15070063) were added to HBSS.  
 
Cell culture media compositions 
DMEM: Dulbecco’s Modified Eagle’s Medium (high glucose 4.5g/l, Gibco 
#41966-029). 
DMEM+: 10% FBS (Hyclone), 10mM Glutamax and Penicillin-streptomycin 
(1000 units) were added to the DMEM 
DMEM/F-12: Advanced Dulbecco’s Modified Eagle’s Medium pre-mixed 1:1 
with F-12 medium (high glucose- 4.5g/l, Gibco #21331-020). 
DMEM/F-12+: 10% FBS (Hyclone), 10mM Glutamax and Penicillin-
streptomycin (1000 units) were added to the DMEM/F-12. 
α-MEM: alpha-Minimum Essential Medium (Gibco #22561-021), 
α-MEM+: 10% FBS (Hyclone), 10mM Glutamax and Penicillin-streptomycin 
(1000 units) were added to the α-MEM medium.  
Cell freezing medium: 50% α-MEM+, 40% FBS (Hyclone), 10% Dimethyl 
Sulfoxide/DMSO (Sigma #D8418) 
 
Chondrogenic medium (per ml): 
Opti-MEM (Gibco #51985-026), 10µl ITS+ premix (contains human 
recombinant insulin 0.6mg/ml, human transferrin 0.6mg/ml, selenous acid 
0.6µg/ml, BSA 125mg/ml, linoleic acid 0.5mg/ml, BD #7341315), 10-6M 
Dexamethasone  (Sigma #D4902), 100µM Sodium L-Ascorbate (Sigma 
#A4034). 
 
Osteogenic medium cocktail (per ml) 
1. DMEM+, 1mg/ml β-Glycerophosphate (Calbiochem #35675), 10-7M 
Dexamethasone and 100µM L-Ascorbate, 1mM Sodium Pyruvate (Sigma 
#S8636). 
 
2. Pre-prepared osteogenic medium premix: Lonza Kit # PT-3002 
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Adipogenic medium cocktail (per ml) 
1. For adult MSCs: 
Induction medium: DMEM+, 1mM Sodium Pyruvate, 100µM Indomethacin 
(Sigma #I7378), 500µM IBMX (3-isobutyl-1-methylxanthine, Sigma #I5879), 
10µg/ml Insulin (Actrapid) 10-6M Dexamethasone and 100µM L-Ascorbate. 
 
Maintenance medium: DMEM+, 1mM Sodium Pyruvate 10µg/ml Insulin 
(Actrapid) 10-6M Dexamethasone and 100µM L-Ascorbate. 
 
2. For P2 MSCs: 
Induction medium: DMEM+, 50ng/ml bone morphogenetic protein-2 (BMP2, 
Sigma #B355). 
 
Maintenance medium: 2µM Rosiglitazone (71740 Cayman), 1µM 
Dexamethasone (Sigma #D4902), 5µg/ml Insulin (Sigma #I9278) and 50ng/ml 
BMP2 along with DMSO control. 
 
9.2.1 Isolation of MSC populations from compact long bones 
Method adapted from previously published protocol (Houlihan et al., 2012). 
Long limb bones (tibias and femurs) from 4-8 weeks old mice were harvested 
and freed from adherent muscle tissues using scalpel and dissection scissors. 
To flush the bone marrow, the epiphysis of bones were cut and long bones 
were spun down at 13,000 rpm (Heraeus Biofuge pico) for 1 minute in a 
punctured 500µl eppendorf tube that is placed in a 1.5 ml eppendorf tube. 
Bones were then washed three times with ice-cold PBS, crushed and cut into 
small pieces in a sterile mortar and pestle that contained HBSS+. A fine, 
paste-like bone mass was prepared using sterile scalpels, replacing the 
HBSS+ at intervals to get rid of remnant bone marrow and adherent 
connective tissues. Long bones from 4-5 adult mice were pooled and digested 
using 2mg/ml (0.19 U/mg) collagenase D (Roche #110882001) in a total of 
20ml of DMEM high glucose medium (pre-warmed to 370C) in a 50ml falcon 
tube incubated for 1 hour at 370C on a shaker at 1100 rpm. After incubation, 
an equal amount of cold α-MEM+ was added to stop the collagenase activity. 
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The cell suspension was filtered through 70µm cell strainer (Falcon #352350) 
into a 50ml Falcon tube kept on ice or at 40C from now on. The digested 
bones were collected again in the sterile mortar in 5ml HBSS+, tapped gently 
using the pestle for ~50 times to homogenize and release the cells from the 
bone. This homogenization step was repeated 6 times to harvest the 
maximum amount of cells. Each time the cell suspension was collected and 
filtered through 70µm cell strainer in the 50ml Falcon tube on ice. Finally, the 
cell suspension was spun in a centrifuge (pre-cooled to 40C) at 1300 rpm for 
10 minutes. The supernatant was aspirated and cell pellets were re-
suspended by gentle tapping until they were fully dispersed. Red blood cells 
were lysed by adding 1ml of ice-cold sterile H2O for 6 seconds, followed 
immediately by addition of 1ml 2x PBS containing 4% FBS and an excess of 
HBSS+. The cell suspension was again filtered through a 70µm sterile cell 
strainer. After recentrifugation, the supernatant was aspirated and cell pellets 
re-suspended in 1-2 ml HBSS+ and filtered through a 50µm sterile cell strainer 
(Partek CellTrics #04-0042-2317). The filtered cell suspension was stained 
with specific antibodies for flow cytometry-based analysis or sorting (see 
9.2.3; 9.8.1). 
 
For isolation of MSC populations from embryonic and early postnatal days, 
same protocol was used with the following few modifications: 
Collagenase digestion step: The duration of incubation of cells with 2mg/ml 
collagenase D at 370C was modified as in Table 9.1: 
Mice stage Time (minutes) 
E10.5 – E12.5 10 
E13.0 – E14.5 15 
E15.5 – E18.5 20 
P1– P3 30 
 Table 9.1 Duration of collagenase digestion for various stages of mice. 
 
The embryonic limb buds were gently pipetted (every 3-5 minutes) during the 
collagenase digestion until a single cell suspension was obtained. 
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Red blood cell lysis: For bones of embryonic and early postnatal day 2 (P2), 
the H2O-lysis step was omitted and red blood cell were removed by extensive 
PBS/ HBSS+ washing and re-centrifugation.  
 
9.2.2 Isolation of embryonic limb bud cells from mice  
Pregnant mice at specific day of gestation were euthanized in a CO2 
inhalation chamber (99.5% at 49.5 bar) and embryos collected in a petri dish 
filled with ice-cold PBS. Embryos were harvested quickly and the head was 
cut before dissecting limb bud using a Leica L2 stereomicroscope. Fore- and 
hindlimb buds were harvested into HBSS+ using bent dissection forceps.  
 
To prepare single cells, the limb buds were incubated in 2% trypsin/PBS at 
40C for 25 minutes, followed by addition of excess serum (Hyclone FBS) to 
stop the trypsin activity. The limb bud ectoderm was removed using soft 
pipettes and a sharp dissection needle. The limb buds were transferred to a 
15 ml falcon tube, containing cell culture medium (DMEM-F12) with 10% FBS 
Hyclone, 10mM Glutamax and Penicillin-streptomycin (1000 units) at 40C 
under the tissue culture hood and a single cell suspension was prepared by 
gentle pipetting. The mesenchymal cell suspension was centrifuged at 1200 
rpm for 5 minutes, filtered using a 70µm cell strainer and re-suspended in cell 
culture media at e.g. 106 cells/ml for analysis or culture. 
 
Cell suspensions to be processed for flow cytometer analysis or sorting were 
incubated in DMEM high glucose medium with 2mg/ml collagenase D at 370C 
for duration as mentioned in table 9.1. During the incubation time, limb buds 
were gently pipetted every 5 minutes until a single cell suspension was 
achieved. Ice-cold HBSS+ was added to stop the collagenase activity, 
followed by centrifugation at 1200 rpm for 5 minutes. Cell pellet was 
resuspended in 1ml HBSS+ and filtered through 50µm sterile cell strainer. 
Cells were then incubated with antibodies (Table 9.9.2) for flow cytometry 
analysis on a BD FACS Canto II (excitation lasers of 405nm: violet; 488nm: 
blue and 633nm: red wavelengths) or sorting on a BD FACS Aria IIITM 
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(excitation lasers of 405nm: violet; 488nm: blue; 561nm: yellow-green and 
633nm: red wavelengths). 
 
9.2.3 Cell sorting and seeding 
Compensations (to avoid “spillover” of the fluorescent emission spectra of the 
different chromophores to other channels) were set up for the BD cell sorter 
and/or analyzer for each panel of antibodies using the BD FACSDivaTM 8.0 
program (Table 8.9.2). Analysis of the cell populations of interest was done 
using the FlowJo vX.0.6 program. Fluorescent dyes, either 0.25µg/ml of 7-
AAD (7-Aminoactinomycin D, Biolegend #420404) or 1µg/ml of DAPI (4',6-
diamidino-2-Phenylindole, Sigma #D952) were added to electronically gate 
out dead cells from the analysis. Populations were defined by examining FSC-
A vs SSC-A on a dot plot to identify and gate the singlet cells. Different cell 
populations were electronically gated and sorted directly into the appropriate 
cell culture medium. Cell re-analysis was always done and the sorting 
enrichment was always between 90-97%. Sorted cells were either plated into 
tissue culture dishes (Falcon) by seeding them at a density of ~5000 cells per 
cm2 or processed for RNA isolation. The culture medium was replaced every 
day to every 3rd day of cell culture depending on the type of assay and cells. 
  
9.3 Cell culture and storage 
9.3.1 MSCs culture and freezing 
Cell culture: Cells seeded at 5000 cells/ cm2 were cultured in α-MEM+ medium 
in tissue culture dishes (Falcon) at in 370C and 5% CO2 in HeraCell 240 
incubator. The culture media was changed every 72 hours. Upon reaching 
confluency, MSCs were split 1:3 as follows: cells were detached in 0.05% 
Trypsin EDTA (Gibco #25300054) for 90 seconds at 37 °C. The resulting 
single cell suspension was collected in 10ml pre-warmed α-MEM+ medium in 
a 15ml Falcon tube and centrifuged at 1200 rpm for 5 minutes. Cell pellets 
were re-suspended in 1ml of α-MEM+ medium and seeded in new tissue 
culture dishes accordingly. MSCs were kept in culture for up to 4 passages.  
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Cell freezing: Cells were detached in 0.05% Trypsin EDTA for 90 seconds at 
370C. The resulting single cell suspension was collected in 10ml pre-warmed 
α-MEM+ medium in a 15ml Falcon tube and centrifuged at 1200 rpm for 5 
minutes. Supernatant was discarded and the tube was gently tapped at the 
bottom to loosen the pellet. To this, 1ml of cold (40C) cell freezing medium 
was added gently (up to 1 x 106 cells per ml) and the cell suspension was 
kept in cryo-tubes at -800C for short-term or -1960C for long-term storage. 
 
9.3.2 Limb bud mesenchymal cell culture 
Single cell suspension of limb buds were prepared from appropriate 
embryonic stages (see before) and then centrifuged at 1200 rpm for 10 min in 
pre-warmed cell culture medium in a falcon tube. The supernatant medium 
was aspirated. Limb bud mesenchymal cell pellets were re-suspended in 1ml 
of cell culture medium and seeded in new tissue culture dishes at the density 
of 5 x 105 – 8 x 105 cells/ cm2. Limb bud mesenchymal cells were not 
passaged or freezed, i.e. always used fresh for analysis.  
 
9.3.3 Colony forming unit fibroblastic (CFU-F) assays  
Freshly sorted MSCs were plated at a density of 1000 cells per 10cm petri 
dish and grown in α-MEM+ medium (370C, 5% CO2). Media was changed 
every 72 hours and cells were cultured for 14 days. The fibroblast-like 
colonies that had formed were fixed with 4% PFA. Then the plates were 
washed with PBS and stained with Toluidine Blue (1 mg/ml, pH 2.3) for 10 
minutes and washed again in PBS. Colonies of more than 50 cells were 
counted and the CFU-F efficiency was calculated as a measure of the 
clonogenicity of MSCs. The CFU-F efficiency was calculated as total number 
of colonies per total number of cells plated and multiplied by 100%. 
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9.4 In vitro cell differentiation assays 
9.4.1 Chondrogenic differentiation of MSCs 
MSCs were plated at high-density or as micromass cultures in 96-well plastic 
plates or 96-well glassbottom microplates (Falcon #353219; for 
immunofluorescence) at 105 cells/well. After overnight in α-MEM+ medium, 
cells were cultured in different chondrogenic differentiation media. To the 
media cocktail, the appropriate combination of 10ng/ml recombinant human 
(rh) ligands such as TGF-βs (TGF-β1, R&D #240-B and TGF-β3, R&D #243-
B3) and BMPs (BMP-2, R&D #355-BM and BMP-4, R&D #314-BP) were 
added to define the conditions to induce chondrogenesis in culture. The 
chondrogenic differentiation medium was changed every 48 hours. For control 
purposes MSCs were cultured in α-MEM+ (expansion medium). All rh ligands 
and additional supplements were kept frozen in small aliquots and added 
freshly to the differentiation medium at the time of changing the media.  
 
9.4.2 Chondrogenic differentiation of MSCs on Collagen type-I matrixes 
12-well tissue culture plates were coated with 2% agarose (Invitrogen 
#16520-050). Sterile Collagen type-I sponge matrixes were prepared to a size 
of 4 mm diameter and thickness and placed in coated wells using 1 µl of PBS 
to keep it stable on the surface. MSCs were pelleted and re-suspended in α-
MEM+ medium at high density (~20,000 cells/µl) and 5 µl of cell suspension 
was carefully pipetted on top of the Collagen type-I matrix. The cells were 
allowed to settle by incubating them for 45 minutes in the tissue culture 
incubator. Then 1ml of pre-warmed α-MEM+ medium was added and cultured 
overnight. The following day, the expansion medium was replaced by the 
appropriate differentiation medium supplemented with growth factors to 
induce chondrogenesis and cells were cultured as described before. 
 
9.4.3 Chondrogenic differentiation of limb bud mesenchymal cells 
Single cell suspensions of embryonic limb cells were prepared in DMEM- 
F12+ and plated in 96-well plate at high density of 2.5-5 x105 cells/well. Cells 
were incubated and media was changed every day.  Limb bud mesenchymal 
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cells adhere to the tissue culture plates and undergo spontaneous 
mesenchymal condensation to initiate chondrogenesis. 
 
9.4.4 Osteogenic differentiation of MSCs 
MSCs were plated in 48-well tissue culture plates at a density of ~20,000 
cells/well. After overnight culture in α-MEM+ medium, the cells were cultured 
in the osteogenic differentiation medium. For MSCs from adult mice, pre-
prepared osteogenic medium from Lonza was used. The differentiation 
medium was changed every 48 hours and osteogenic differentiation was 
analysed after 14-21 days. To study the osteogenic differentiation potential of 
MSCs from postnatal day P2 mice, the DMEM+-based osteogenic medium 
was used and 10 ng/ml BMP4 added each time the medium was changed. As 
a control for both assays, MSCs at same density were cultured for same time 
in α-MEM+ medium. 
 
9.4.5 Adipogenic differentiation of MSCs 
MSCs were plated in 48-well plates at ~20,000 cells/well. After overnight 
culture in α-MEM+ medium, MSCs from adult mice were cultured in the 
differentiation medium consisting of an insulin-based induction medium for 72 
hours followed by expansion medium for 24 hours. This 96-hour cycle was 
repeated 3 times followed by 7 days of culture in maintenance medium. As 
control, MSCs were cultured at same density and duration in α-MEM+ 
medium. MSCs from postnatal P2 mice were seeded into 8 well µ-slide (Ibidi 
#80826) for immunofluorescence or into 48-well plates for RNA extraction at 
~20,000 cells/well. After overnight culture, the α-MEM+ medium was replaced 
with DMEM+ containing BMP2 (B3555 Sigma) at concentration of 50ng/ml. 
After 72 hours, the medium was changed to DMEM+ containing 2µM 
Rosiglitazone, 1µM Dexamethasone, 5µg/ml insulin and BMP2 along. After an 
additional 48 hours, cells were either harvested (day 5) for analysis or the 
culture was continued by repeating the treatment with the different media for 
another cycle and harvesting the cells for analysis at 10 days of 
differentiation. Control cells were grown in α-MEM+ medium supplemented 
with an equal concentration of DMSO as the differentiation medium. 
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9.5 Engraftment of cartilage templates derived from differentiated 
MSCs into nude mice 
In vivo experiments using nude mice (CD-1 nude/nude) involved engraftment 
of expanded MSCs and cartilage templates derived from MSCs seeded into 
collagen type-I scaffold and having undergone chondrogenic differentiation. 
 
9.5.1 Subcutaneous implantation into nude mice 
This procedure was performed by Dr. Atanas Todorov and Alexander 
Haumer, together with technical assistance of Dr. Andrea Barbero in the 
group of Prof. Ivan Martin at the University Hospital of Basel. 
 
MSC derived-cartilage templates and controls were implanted into 
anesthetized adult nude mice. Two small incisions on the epidermis and 
dermis  (approx. 10mm) were made on the center back of the shoulder and 
waist under sterile conditions. The seeded and differentiated Collagen type-I 
matrixes were placed through the incisions in the subcutaneous pockets (up 
to 4 constructs per mice). Incisions were then stapled and mice monitored 
until they wake-up under the warming red light source. After transferring the 
operated mice to their cages, they received the analgesic Buprenorphine 
(2mg/Kg) every 12 hours for the first 48 hours. After the surgery, the health of 
all mice was monitored every day for the duration of the experiment to detect 
possible wound infections or other complications. In no case wound infections 
or other complications were observed. Staples were removed after wound 
healing was complete (1 - 2 weeks) and the implants remained up to 8 weeks 
prior to analysis. 
 
9.5.2 Analysis of the nude mouse implants  
After euthanizing the experimental nude mice, the implants were resected by 
removing most of the host tissue and blood vessels surrounding them. The 
constructs were washed in PBS, cleaned further and fixed in 4% PFA in PBS 
overnight at 40C. The calcified constructs were incubated in decalcification 
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buffer (7% w/v EDTA, 10% w/v sucrose in PBS) for 24-48 hours at 370C on a 
rotator before processing them for histology and/or analysis by 
immunofluorescence. 
 
9.6 Histology 
9.6.1 Cryo-embedding  
Fixed tissue samples or cell constructs were rinsed 2x in PBS and passed 
through a graded series of sucrose/PBS (w/v) at 40C: 10% sucrose, 20% 
sucrose, 30% sucrose; each incubation step ranging from 30 minutes to 1 
hour; i.e. samples had to be equilibrated completely at each step. Then, the 
samples were transferred to an embedding mold (Sakura Tissue-Tek 4565) 
and the 30% sucrose was carefully removed. Optimum Cutting Temperature 
(OCT) embedding medium was mixed with 30% sucrose at 50:50 (v/v) was 
carefully added to the samples in the embedding molds. These were then 
frozen using 2-methylbutane by dry ice and the frozen blocks stored at -800C 
until cryosectioning. 
 
9.6.2 Paraffin embedding 
Fixed tissues samples or cell constructs were rinsed 3x in PBS and 
dehydrated in a graded series of ice-cold EtOH: 25% EtOH, 50% EtOH, 75% 
EtOH, 100% EtOH (2 times); each incubation step ranging from 5 minutes to 
30 minutes depending on the type of tissue. Then the samples were cleared 
in Xylene for 2x 30 minutes at room temperature, followed by 30 minutes 
incubation in 50:50 (v/v) Xylene/paraffin wax at 600C. Samples were then 
treated with freshly melted paraffin for ≥3x at 600C for 1 hour. Then they were 
embedded in fresh paraffin (600C) using a stereomicroscope for positioning 
the tissue in the embedding cassettes (Kaltek #2882). The blocks were cooled 
to solidify the paraffin, after which they were stored at 40C. 
 
9.6.3 Sectioning of embedded samples for fluorescent microscopy 
Sectioning of OCT embedded samples was performed using Microm HM 500 
OM Cryostat (-20°C). The sectioning blade was cooled down to -220C and 
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frozen blocks were transferred from -800C storage to the cryostat chamber. 
The thickness of sections ranged from 8µm-30µm. Sections were mounted on 
Superfrost Plus slides (Thermo Scientific) and stored at -800C. 
 
Paraffin embedded samples were sectioned using Microm HM 355 
microtome, the sectioning blade was cooled down to 100C and a water bath at 
400C was used to stretch the sections on the glass slides. 7µm-10µm sections 
were cut and mounted on Superfrost Plus slides (Thermo Scientific), which 
were stored at room temperature. 
 
9.6.4 Alcian Blue staining 
Alcian blue staining was performed on chondrocytes to detect the 
glycosaminoglycans (GAGs) produced during chondrocyte differentiation. The 
medium was carefully aspirated from differentiated cells, which were then 
fixed for 30 minutes in 4% PFA in PBS. After aspirating the 4% PFA and 3x 
washing in double-distilled H2O (ddH2O; 5 minutes each), the Alcian blue 
staining (1%, prepared with 3% acetic acid solution in ddH2O, pH = 1.0; 
Sigma #A3157) was done overnight at room temperature. The dye was 
washed using ddH2O and samples were analyzed and documented using a 
Leica DMI-4000 microscope. 
 
9.6.5 Alizarin Red-S staining 
Alizarin Red-S staining was performed to detect the calcium deposits 
produced by differentiated osteoblasts. The medium was carefully aspirated 
and cells were fixed for 30 minutes in 70% EtOH at 40C. After aspirating the 
70% EtOH and 3x washing in ddH2O for 5 minutes each, the Alizarin Red-S 
staining (2mg/ml, prepared in ddH2O, pH = 4.1 - 4.3; Sigma #A5533) was 
done for 1 hour at room temperature. The dye was washed off in ddH2O and 
samples documented using a Leica DMI-4000 microscope. 
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9.6.6 Oil Red-O staining 
Oil Red-O staining was performed to detect the lipid droplets in differentiated 
adipocytes. The medium was aspirated and cells were fixed for 30 minutes in 
4% PFA in PBS at RT. After washing, cells were treated with 60% isopropanol 
for 5 minutes at room temperature. Then the isopropanol was substituted by 
Oil Red-O solution. The stock solution is prepared at 3mg/ml in 99% 
isopropanol and is stable for (~1 year; Fisher #M312512), the working solution 
prepared by mixing 3 parts of the stock solution with 2 parts of de-ionized H2O 
and leaving them for 10 minutes at room temperature. Cells are incubated 
with prepared working solution for 5 minutes at room temperature. The Oil 
Red O solution was washed off in tap water. Cells are then counterstained by 
Hematoxylin solution (Sigma #H3136) for 1 minute at room temperature. Then 
they are rinsed again with tap water to remove the excess Hematoxylin. 
Samples were documented using a Leica DMI-4000 microscope. 
 
9.6.7 Safranin-O staining 
Safranin-O staining was performed to detect the presence of sulfated 
glycosaminoglycans (GAGs), produced by chondrocytes and in chondrogenic 
tissues. The medium was carefully aspirated and samples fixed for 30 
minutes in 4% PFA in PBS. PFA was removed and specimens were washed 
in tap water for 5 minute followed by staining in 0.02% fast green (Sigma 
#F7252) for 4 minutes at room temperature. Cells were then dipped 3x in 1% 
acetic acid solution. Then, the Safranin-O staining (0.1% prepared in ddH2O; 
Sigma #HT904) was done for 6 minutes at room temperature. Samples were 
thhen dehydrated by dipping them in a series of 95% EtOH to 100% EtOH (10 
dips each), followed by washing them for 2x 1 minute in Xylene. The samples 
on slides were mounted in Eukitt (Fluka #03989) and documented using the 
Leica DMI-4000 microscope. 
 
9.6.8 Hematoxylin/ Eosin (H&E) staining 
Fixed specimens were washed extensively in tap water for 5 minutes. 
Hematoxylin staining was done by incubating the sections 3x in the filtered 
solution of Hematoxylin series (90 seconds each), followed by washing in tap 
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water for 2 minutes. Further staining was performed using filtered 0.10% 
Eosin Y/EtOH (Sigma #E4382). Cells were dehydrated in a series of 95% 
EtOH to 100% EtOH, 5 minutes each followed by 2x washing in Xylene for 5 
minutes each time. Samples on slides were then mounted in Eukitt (Fluka) 
and documented using the Leica DMI-4000 microscope. 
 
9.7 Molecular Biology 
9.7.1 DNA extraction for genotyping of mice strains 
Tail or ear clips from mice were placed in 400µl of tail buffer (10 mM Tris HCl 
pH 8.0, 50 mM EDTA, 100 mM NaCl, 0.5% SDS) including 40µl Proteinase K 
(1µg/ml) (Merck #24568) and incubated overnight in thermostat at 550C with 
rotation at 750 rpm. The following day, tail buffer was added to a total volume 
of 750µl and samples mixed on a rotator for 2 minutes. 250µl of 6M NaCl was 
added to the sample and mixed on a rotator for 2 minutes, followed by 
centrifugation at 13,000 rpm for 10 minutes. 75µl of clear supernatant was 
collected in fresh eppendorf tube, to which 500µl of isopropanol was added, 
mixed and spun down at 13,000 rpm for 5 minutes at room temperature. The 
supernatant was removed and the DNA pellets were washed with 70% 
ethanol and re-centrifuged. Pellets were then air-dried and re-suspended in 
100-500µl of TE buffer (10 mM Tris HCl pH 8.0, 100µM EDTA). The re-
suspended samples were incubated in Thermostat mixer at 550C for 10 
minutes to dissolve the DNA and then stored at 40C. 
 
9.7.2 RNA extraction using TRI-Reagent solution 
Tissue samples or cells (embryonic limb bud cells or sorted MSCs) in 
monolayer or high-density culture were detached by controlled trypsin 
digestion (see before) and transferred into 1ml Tri-Reagent solution (Sigma 
#T9424) in eppendorf tubes. Samples were then homogenized by passing 
them several times through syringe with a 21G needle. For small amounts of 
cells, 10µl of 0.5% LPA (Linear Polyacrylamide) were added per 1ml of Tri- 
Reagent to act as carrier for precipitation of small amounts of RNA. 
Homogenates were left to rest for 10 minutes at room temperature, then 200µl 
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of chloroform (Sigma #372978) was added and the samples were vigorously 
shaken for 15 seconds. Samples were again incubated for 15 minutes at room 
temperature and then spun at 12,000 rpm in a 40C pre-cooled centrifuge to 
separate the phenol-chloroform from the aqueous phase. The aqueous phase 
was collected carefully into a fresh RNAse-free eppendorf tube and 0.5ml of 
isopropanol (Merck) was added. Samples were incubated for 10 minutes at 
room temperature to precipitate the RNA and then centrifuged at 12000g and 
at 40C for 10 minutes. The supernatant was removed and the RNA pellets 
washed with 75% EtOH, followed by re-centrifugation at 7500g at 40C for 5 
minutes. The RNA pellets were then air-dried quickly and dissolved in DEPC 
(Diethylpyrocarbonate)-treated water in 20µl -50µl; depending on the amount 
of RNA. The samples were then incubated for 10 minutes at 550C to dissolve 
the RNA pellet and the RNA concentration quantified using the Nanodrop 
2000C machine (Thermo Scientific). 
 
9.7.3 DNase treatment of RNA samples 
Samples with up to 2 µg of total RNA were treated as follows: 2µl of 10x 
DNase TURBO buffer (Ambion #4022G) and 1.5µl of TURBO DNase (2U/µl, 
Ambion #AM2238) were added and gently mixed. DEPC-treated water was 
added to a final volume of 20µl per sample. The samples were then incubated 
for 15 minutes at room temperature, followed by addition of 1µl of EDTA (25 
mM) per sample and 15 minutes incubation at 650C. Then, samples were 
transferred to ice and stored at -200C. 
 
9.7.4 cDNA synthesis 
For cDNA synthesis, 10pg-5µg RNA were mixed with: 1µl of oligo dT12-18 
(500ng); 1µl of dNTP mix (10mM each of dATP, dGTP, dCTP and dTTP at 
neutral pH); sterile H2O to a total volume of 13 µl. The reaction mixture was 
heated at 650C for 5min and incubated on ice for ≥1 minute. Then the 
following reagents were added to this reaction mixture: 4 µl of 5x first strand 
buffer, 1µl of 0.1M DTT, 1µl of RNaseOUTTM 40U/µl, 1µl of SuperscriptTM III 
reverse transcriptase (200U/µl; reagents from the Invitrogen kit). The mixture 
was then incubated for 1 hour at 500C, followed by heat inactivation for 15 
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minutes at 700C. The cDNA samples were stored at -200C. 
 
9.7.5 Real-time quantitative PCR (RT-qPCR) 
The Bio-Rad CFX96 Real-Time PCR system was used in together with iQ 
SYBR Green Supermix (Bio-RAD). RT-qPCR was used to quantify the gene 
expression levels in cells and tissues. 0.3µM of specific primers (Table 9.9.1) 
were diluted in EB buffer (10 mM Tris-HCl, pH 8.5) and used for PCR 
amplification. The reaction mixture also contained 50% SYBR Green and 
DNA template and the total volume of 20µl was prepared using milli-Q H2O. 
Gene expression levels were quantified from cDNA templates analyzed in 
biological duplicate or triplicate replicates. Primers to amplify housekeeping 
genes (Table 9.9.1) were used as endogenous controls and to normalize 
gene expression levels between different samples. The Cq values of the 
transcripts of interest were normalized in relation to the Cq values of these 
controls and normalized fold expression levels (2-ΔΔCq) of target transcripts 
were calculated with mean standard deviation, relative to the mean value of 
control sample. 
 
9.8 Immunofluorescence (IF) analysis 
9.8.1 Live cell staining for flow cytometry 
Suspensions were prepared in HBSS+ from freshly isolated cells (see before) 
or by collagenase treatment (2 mg/ml) of monolayer cultures. Monolayer 
cultures were washed with PBS prior to addition of 2 mg/ml Collagenase D 
and incubation at 370C for 10 minutes. Cells were then detached by flicking 
the dishes few times or using sterile cell scrappers (Sarstedt #83.1830). 
Collagenase was inhibited by addition of serum, followed by washing and 
centrifugation with HBSS+. Cells were resuspended in HBSS+ and filtered 
through a 70µm strainer, followed by incubation with primary antibodies 
(Table 9.9.2) for 20 minutes at 40C. Cells were then spun at 2,400 rpm for 4 
minutes and pellets were re-suspended in HBSS+. Since lineage markers are 
labeled with biotin, a second incubation with streptavidin conjugated to 
different chromophores was done for 5 minutes at 40C (Table 9.9.2). Cells 
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were spun down and re-suspended in HBSS+ again before flow cytometric 
sorting or analysis.  
 
9.8.2 Immunofluorescence analysis of monolayer cell cultures 
Cells were cultured as monolayers or high-density micromasses in 96-well 
glass bottomed optical tissue culture microplates (Falcon #353219). Then, 
cells were washed 2x in PBS prior to fixation in 4% PFA in PBS for 30 
minutes at room temperature. After fixation and washing in PBS, antigen 
retrieval was performed for specific antibodies by incubating the cells in 250 
µg/ml of pepsin (Sigma #P6887) at 370C for 10 minutes. Following two 
washes in PBS for 5 minutes each, cells were incubated in permeabilization 
buffer (PBS with 0.3% Triton-X100) for 20 minutes at room temperature. 
Following permeabilization, the blocking step was performed using 
permeabilization buffer with 10% of either goat or donkey serum for 1 hour at 
room temperature. The incubation with primary antibodies (Table 9.9.2) was 
done overnight at 40C. The following day, cells were washed 3x in PBT for 5 
minutes each and incubated with secondary antibodies (Table 9.9.2) for 1 
hour at room temperature. Following 3 washes with PBT for 5 minutes each, 
nuclei were counterstained with 1 mg/ml of Hoechst-33258 in PBS for 5 
minutes. Cells were washed again 3x in PBT and stored in PBS at 40C until 
image acquisition. 
 
9.8.3 IHC on frozen sections 
Frozen tissue sections were left at RT for 10 minutes, followed by washing 
step for three times in PBS (5 minutes each). Slides were marked with 
hydrophobic border around the tissue section, using Dako pen (Dako 
#S2002). Antigen retrieval for specific antibodies was performed 
enzymatically by incubating the plates in 250 µg/ml of pepsin for 10 minutes 
at 370C. Steps of blocking, antibody staining and nuclear staining was 
performed as in section 9.8.2, after which the tissue was washed in PBS and 
mounted using Mowiol 4-88 (Calbiochem #475904) and covered with a glass 
cover slip. Mounted slides were dried overnight at RT and stored until image 
acquisition. 
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9.8.4 Immunofluorescence analysis using paraffin embedded tissue 
sections 
Slides with tissue sections were de-paraffinized by incubating them 2x in 
Xylene (10 minutes each), followed by 2x 100% EtOH (10 minutes each) at 
room temperature. Sections were then rehydrated in a reverse EtOH series- 
70% EtOH/H2O, 50% EtOH/H2O, 30% EtOH/H2O (5 minutes each) and rinsed 
2x in H2O and PBS each. Antigen retrieval on sections for specific antibodies 
was done by autoclaving at 1200C in 10mM sodium citrate buffer (pH 6.0) with 
0.05% Tween-20 for 6 min. Blocking steps, incubation with primary and 
secondary antibodies and counterstaining of nuclei was done as described in 
the previous section. Finally the slides were washed in PBS and mounted in 
Mowiol 4-88 and covered by a glass coverslip. Mounted slides were dried 
overnight at room temperature and stored at 40C. 
 
9.8.5 BrdU labeling of proliferating cells 
In order to label the proliferating limb bud cells in mouse embryos with BrdU, 
1 mg of BrdU (BD Pharmingen BrdU kit #552598, dissolved in 1X DPBS) was 
administered twice to the pregnant female by intraperitoneal injection (IP), 4 
and 2 hours prior to euthanasia and embryo isolation. Limb buds from the 
correct embryonic stages were collected for fixation and further analysis by 
immunofluorescence. For negative controls, mice were injected (IP) with 1x 
DPBS and limb buds from same stages were collected.  
 
Cultured cells were labeled by adding 10 µM of BrdU to the culture medium. 
Treatment was done for 30 minutes and then cells were either fixed for 
immunofluorescence analysis or detached for flow cytometry (see before). 
First, cells were incubated with cell-surface markers using the appropriate 
fluorescent antibodies (Table 9.9.2) for 15 minutes at 40C. Then cells were 
washed in HBSS+, fixed, permeabilized and BrdU positive cells were detected 
by immunofluorescence using the BD PharmingenTM BrdU Flow kit according 
to the manufacturers instruction manual. 
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9.8.6 BrdU detection by immunofluorescence on tissue sections 
4% PFA-fixed cells in 96-well glass bottomed optical tissue culture plates or 
tissue cryo-sections on slides were rinsed 2x with PBS and permeabilized in 
0.3% Tween-20 in PBS for 20 min at room temperature. DNA denaturation 
was performed in 1N HCl for 10 min and 2N HCl for 10min at room 
temperature. Then the samples were incubated at 37°C for 20min and 
neutralized with 0.1 M pH 8.6 Borate Buffer for 15min at room temperature. 
Next, samples were blocked in 10% goat serum and 0.3% Triton-100 in PBS 
for 1 hour, followed by incubation with anti-BrdU antibody (Bio-Rad clone 
BU1/75). The samples were then washed 3x in PBS, followed by incubation in 
secondary antibody for 1 hour at room temperature. After 3 washes in PBS, 
nuclei were detected with 1 mg/ml of Hoechst-33258 in PBS for 5 min, 
followed by 3 washes in PBS.  Slides were mounted using Mowiol and stored 
at 40C in the dark. Immunofluorescence images were obtained using a Leica 
Sp5 confocal microscope and processed using Photoshop CS5 for Macintosh. 
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9.9 Tables  
9.9.1 List of primers 
Genotyping PCR 
Locus Forward primer Reverse primer Allele 
CMVCre 5’ GCCTGCATTACCGGTCGATGCAACGA 3’ 5’ GTGGCAGATGGCGCGGCAACACCATT 3’ Tg 
TmCre 5’ CTCTAGAGCCTCTGCTAACC 3’ 5’ CCTGGCGATCCCTGAACATGTCC 3’ Tg 
DsRed 5’ GGTGATGTCCAGCTTGGAGT 3’ 5’ CCCCGTAATGCAGAAGAAGA 3’ Tg 
β-actin-GFP 5’ CATGAAGCAGCACGACTTCT 3’ 5’ GCTTGTCGGCCATGATATAG 3’ Tg 
Sox9-GFP 5' CCTACGGCGTGCAGTGCTTCA GC 3' 5' CGGCGAGCTGCACGCTGCCGT CC 3' Tg 
 
     
 
qPCR primers 
Locus Forward primer Reverse primer Size 
Sox9 5’ CAAGTGTGTGTGCCGTGGATAG 3’ 5’ CCAGCCACAGCAGTGAGTAAGA 3’ 89 
Col2a1 5’ AGTGGAAGAGCGGAGACTACTG 3’ 5’ TTGGGGTAGACGCAAGTCTC 3’ 106 
Col10a1 5’ GCTAATGTTCTTGACCCTGGT 3’ 5’ TGTTCTCCTCTTACTGGAATCC 3’ 150 
Osterix 5’ CCTCGCTCTCCTATTGCA 3’ 5’ GCAAAGGCCTGAGAGGAGTT 3’ 70 
Osteocalcin 5’ TGTGACGAGCTATCAGACCAGT 3’ 5’ GCTGTGACATCCATACTTGCAG 3’ 177 
PPAR-γ 5’ GCTGTGAAGTTCAATGCACTGG 3’ 5’ GCAGTAGCTGCACGTGCTCTG 3’ 250 
FABP4 5’ GATGCCTTTGTGGGAACCT 3’ 5’ CTGTCGTCTGCGGTGATTT 3’ 230 
RPL19 5’ ACCCTGGCCCGACGG 3’ 5’ TACCCTTTCCTCTTCCCTATGCC 3’ 53 
 
 
9.9.2 List of primary and secondary Antibodies 
Primary Antibodies 
Antigen and Host Distributor/ clone Dilutions Usage Comment 
Anti-BrdU rat Bio-Rad 
clone BU1/75 (ICR1) 
1:1000 IHC Monoclonal 
Anti-BrdU  mouse eBioscience 
clone BU20A 
1:200 FACS Monoclonal 
B220 mouse Biolegend  
clone RA3-6B2 
1:1000 IHC Fluorophore 
conjugated 
CD105 mouse Biolegend  
clone MJ7/18 
1:500 FACS Fluorophore 
conjugated 
CD117/ c-kit mouse Biolegend  
clone 2B8 
1:250 FACS Fluorophore 
conjugated 
CD11b mouse BD Biosciences  1:1000 FACS Biotinylated 
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clone M1/70 
CD200 mouse Biolegend  
clone OX-90 
1:1000 FACS Fluorophore 
conjugated 
CD3 mouse Biolegend  
clone 145-2C11 
1:250 FACS Biotinylated 
CD31 mouse eBioscience  
clone 390 
1:1000; 1:250 FACS Biotinylated  
CD31 mouse Biolegend  
clone MEC13.3 
1:250 IHC Fluorophore 
conjugated 
CD34 mouse Biolegend  
clone MEC14.7 
1:250 FACS Fluorophore 
conjugated 
CD44 mouse Biolegend  
clone IM7 
1:5000 FACS Fluorophore 
conjugated 
CD45  mouse  BD Pharmingen  
clone 30-F11 
1:500 FACS Biotinylated 
CD45 mouse Biolegend  
clone 30-F11 
1:250 IHC Fluorophore 
conjugated 
CD49e mouse eBioscience  
clone eBioHMa5-1 
1:1000 FACS Fluorophore 
conjugated 
CD51 mouse Biolegend  
clone RMV-7 
1:1000 FACS Fluorophore 
conjugated 
CD73 mouse eBioscience  
clone eBioTY/11.8 
1:1000 FACS Fluorophore 
conjugated 
CD90 mouse eBioscience  
clone 53-2.1 
1:2000 FACS Fluorophore 
conjugated 
COL-II mouse Thermo Scientific 
clone 2B1.5 
1:300 IHC Monoclonal  
COL-X rabbit Abcam 
Cat. #ab58632 
1:300 IHC Polyclonal  
Ep-CAM mouse Biolegend  
clone G8.8  
1:1000 FACS Biotinylated  
F4/80 mouse Biolegend  
clone BM8 
1:1000 FACS; IHC Biotinylated 
Flk-1 mouse Biolegend  
clone 89B3A5 
1:1000 FACS Biotinylated 
Gr-1 mouse Biolegend  
clone RB6-8C5 
1:1000 FACS Biotinylated 
OSTERIX rabbit Abcam 
Cat. #ab94744 
1:2000 IHC Polyclonal  
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Secondary Antibodies 
Antigen Manufacturer Dilution Usage 
Donkey α Rat IgG (H+L) Alexa Fluor® 555 Invitrogen, 
A21209 
1:500 IHC 
Goat α Mouse IgG (H+L) Alexa Fluor® 488 F(ab’)2 Invitrogen,  
A-11017 
1:500 IHC 
Goat α Mouse IgG (H+L) Alexa Fluor® 594 F(ab’)2 Invitrogen,  
A-11020 
1:500 IHC 
Goat α Rabbit Alexa Fluor® 555 Invitrogen, 
A21428 
1:500 IHC 
Goat α Rabbit IgG (H+L) Alexa Fluor® 594 Invitrogen, 
A11037 
1:500 IHC 
Goat α Rabbit IgG (H+L) Alexa Fluor® 594 Invitrogen,  
A-11070 
1:500 IHC 
Goat α Rat Alexa Fluor® 555 Invitrogen, 
A21434 
1:500 IHC 
Ms X Fluorescein Alexa Fluor® 488 Millipore 
MAB045X 
1:500 IHC 
Rabbit α Goat IgG (H+L) Alexa Fluor® 594 Invitrogen,  
A-11080 
1:500 IHC 
 
     
 
 
 
PDGFR-α mouse Biolegend  
clone APA5 
1:250; 1:1000 FACS; IHC Fluorophore 
conjugated 
PDGFR-β mouse eBioscience 
clone APB5 
1:250 FACS Fluorophore 
conjugated 
PPAR-γ rabbit Cell Signaling  
Cat. # 2443 
1:1000 IHC Monoclonal 
Sca-1 mouse Biolegend  
clone D7 
1:10000; 
1:200 
FACS; IHC Fluorophore 
conjugated 
SOX9 rabbit Millipore 
Cat. # AB5535 
1:5000 IHC Polyclonal  
Streptavidin  Biolegend 1:1000 FACS Affinity to Biotin 
TER119 mouse Biolegend 1:200 FACS Biotinylated 
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9.9.3 List of additional reagents 
Product Manufacturer/ Reference 
100% Acetic acid Merck #100063 
2-Propanol Merck #109634 
36.5% formaldehyde Sigma #252549 
Agarose (PCR) Biozym #335010 
Bovine Serum Albumin (BSA) Sigma, #A3059 
Bromophenol Blue Sigma #B5525 
Chloroform Sigma #372978 
EDTA Sigma #E5134 
Entellan Merck #HX825968 
Eukitt Fluka #03989 
iQ™ SYBR® Green Supermix  Bio-Rad #170-8882 
Oligo(dT)12-18 Invitrogen #18418-012 
Paraplast for embedding (Paraffin) Sigma #P3558 
RNaseOUTTM  Ribonuclease Inhibitor  Invitrogen #10777-019 
SuperScriptTM  III Reverse Transcriptase  Invitrogen #18080-044 
Toluidine Blue Sigma X4126 
Xylene Applichem #A2476 
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12. Appendix 
 
I: Cell cycle analysis of PαS cells in culture by BrdU incorporation 
and 7AAD DNA content 
 
 
 
Fig. I (A) Cell cycle analysis of PαS cells expanded in vitro by BrdU incorporation and DNA 
content (stained with 7AAD). This combination detects apoptotic cells (Ap.) and resolves cell 
cycle phases into S, G0/G1, and G2/M phases as shown in the right panel. c.a. = cell 
aggregates. (B) Phases of cell cycle in the 4 subpopulations of PαS cells (q1, q2, q3 and q4). 
A cells from q3 subset shows maximum BrdU incorporation (S phase 96%), followed by q1 
(93%), q2 (84%) and q4 (68%). 
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II: Development of HSCs/HPCs pool from fetal liver till postnatal 
bone 
 
Fig. II: Representative gatings on LSK cells (Sca1+c-Kit+ fraction from Lin- fraction) of from 
liver and crushed bone are shown in the left panels. Combination of CD150 (SLAM) and 
CD34 splits the LSK cells into long term (which lies in LSKCD34- subset) and short term 
(which lies in LSKCD34+ subset) HSCs, shown in the right panel. ‘Lin’ fraction constitute of 
cells positive for: CD3, Gr-1, FLK-1, PDGFRα, CD31, CD11b, and Ter119. 
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III: PαS cells maintain the expression of CD90 and CD73 for few 
days in culture 
  
The in vitro and in vivo assays with PαS cells (and their subpopulations) were 
performed after a short-term expansion (5 days) of these cells in serum-based 
culture medium. This period of time for expansion of cells was chosen after 
establishing that the CD signature of these cells do not change over a short 
time of expansion and hence would not compromise the multilineage potential 
in trilineage assays.  
 
 
 
Fig. III: (A) Representative gatings for CD90 and CD73 expression on freshly isolated PαS 
cells from P2 mice. (B) Representative gatings for CD90 and CD73 expression on PαS cells 
(from A) after 5 days in culture.  
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IV: In vitro chondrogenic differentiation of PαS cells do not mature 
to hypertrophy during the time of chondrogenic differentiation 
 
 
Fig. IV: mRNA fold change of Col10a1 in adult PαS cells during chondrogenic differentiation 
at day 7 and day 14. E14.5 Limb is set as positive control to set Col10a1 expression to 1.0. 
Control = PαS cells at high density in expansion medium; (+)ve Control is limb cells from 
E14.5.  Tp = PαS cells at high density in ‘Tp’ differentiation medium; T+B = PαS cells at high 
density in ‘T+B’ differentiation medium. 
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V: PαS cells that express CD15 (Stage-Specific Embryonic 
Antigen-1 or SSEA-1) lie as a small fraction of q3 (PαS+CD90-CD73) 
subpopulation 
 
 
 
Fig. V: (A) Representative gatings and histogram of CD15+ cells in PαS subpopulations (q1-
q4, left panel) of adult mice. CD15+ cells (shown in green) are located in the q3 subpopulation 
of PαS cells (shown in red). CD15+ cells constitute ~10% of q3 subpopulation (3rd panel and 
histogram) (B) Representative gatings and histogram of CD15+ cells in PαS subpopulations 
(q1-q4, left panel) of P2 mice. CD15+ cells (shown in green) are located in the q3 
subpopulation of PαS cells (shown in red). CD15+ cells constitute ~20% of q3 subpopulation 
(3rd panel and histogram). 
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VI: In vivo fate of PαS, PαS+CD90+ and PαS+CD90- subsets from 
E18.5 
 
(a) 
 
Fig. VI (a). Cartilage templates derived from perinatal (E18.5) PαS+CD90+ cells are only 
partially remodeled into bone, which attracts endothelial cells (A, D, F) Undifferentiated 
control implants. (B, C, E, F, H, I) Immunofluorescence analysis of the Osterix (OSX in red) 
and CD31 (green) distributions in implants derived from PαS (B, C), PαS+CD90+ (E, F) and 
PαS+CD90+ cells (H, I). Nuclei are detected by Hoechst (blue). Scale bar = 100 µm. (n= 3 
independent experiments). 
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(b) 
 
Fig. VI (b). PαS+CD90+ derived implants support B-cell development at the site of bone 
formation. (A, D, F) Representative area of undifferentiated control implants (B, C, E, F, H, I) 
immunofluorescent analysis of the B220 (red) distribution in implants of PαS (B, C), 
PαS+CD90+ (E, F) and PαS+CD90+ cells (H, I). Nuclei are detected by Hoechst (blue).  Scale 
bar = 100µm. (n= 3 independent experiments). 
 
 
 
 
 
 
 
 
 
 
 
 143 
 
(c) 
 
 
Fig. VI (c). Implants from PαS+CD90+ derived implants support hematopoiesis (HPCs) at 
sites of bone formation. (A, D, G) Representative area of undifferentiated control implants. 
(B, C, E, E’, F, F’, H, I) Immunofluorescent analysis of the distribution of the CD45 (red) and 
Sca1 (green) on sections of implants derived from PαS (B, C), PαS+CD90+ (E, E’, F, F’) and 
PαS+CD90+ cells (H, I). Cells co-expressing Sca1 and CD45 were detected (E’, solid 
arrowhead. In addition, Sca1 single positive cells were also detected (E’, hollow arrowhead). 
(H, I) Only few CD45-positive cells were detected in PαS+CD90- derived implants and 
controls. Nuclei are detected by Hoechst (blue). Scale bar = 50µm. Scale bars for 
enlargements (E’, F’) = 10µm. (n= 3 independent experiments). 
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VII: Manuscript in preparation (1)  
 
“Characterization of early mouse mesenchymal stem/progenitor cells for 
generating cartilage and study their role in endochondral ossification”   
 
Sumit Jaiswal1*, Gretel Nusspaumer1*, Andrea Barbero1, Atanas Todorov1, 
Dana Ronen1, Gerhard Christofori1 Ivan Martin1, Rolf Zeller1 
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*The project details are discussed as a part of this thesis work. 
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VIII: Manuscript in preparation (2) 
 
“Quantitative analysis of vertebrate limb bud growth and proliferation 
kinetics” 
 
Erkan Ünal1,2,3, Jannik Vollmer2,3, Gretel Nusspaumer1, Sumit Jaiswal1, Rolf 
Zeller1*, Dagmar Iber2,3* 
 
1Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, Switzerland  
2Department of Biosystems, Science and Engineering (D-BSSE), ETH Zurich, Switzerland  
3Swiss Institute of Bioinformatics (SIB), Mattenstraße 26, 4058 Basel, Switzerland 
 
Abstract: The cellular and molecular mechanisms controlling organ size have 
remained rather elusive and quantitative data are largely missing to evaluate 
models and hypotheses in mammalian systems. We combined limb bud 
mesenchyme specific reporter gene expression with FACS (fluorescent-
activated cell sorting) analysis and 3D imaging to generate quantitative 
datasets for mouse and chicken limb buds. In particular, with have quantitated 
mesenchymal cells numbers for mouse forelimb buds. This analysis reveals 
the striking biphasic behaviour of limb bud growth in both species. In spite of 
the growth rates being higher in chicken than mouse forelimb buds, the switch 
in growth behaviour occurs upon reaching similar mesenchymal cell numbers 
in both species. This switch point coincides with the time window during which 
the autopod primordia (hand plate) forms, but the slower proliferation of the 
SOX9-positive osteo-chondrogenic progenitors cannot account for the 
observed switch to lower limb bud growth. Rather, the biphasic growth 
behaviour is the result of the continuous decline in proliferation of all limb bud 
mesenchymal cells. The experimental results are computationally analysis 
using different growth laws for simulations. Intriguingly, the growth behaviour 
of the Drosophila wing disc can be described with the same growth laws. This 
raises the possibility of an evolutionary conserved mechanism for growth 
control that is not per se linked to a specific tissue-patterning program.  
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My contribution to this project was to perform the BrdU incorporation studies 
in mouse embryonic limb bud at different somite stages and analyse them 
through fluorescent microscopy. I analysed the limb progenitor cells that were 
in proliferative state (BrdU labelling) and that were committed towards osteo-
chondro-lineage (Sox9+) (Fig. VIII). These results validated the flow cytometry 
based analysis performed at same somite stages of mouse limb buds and 
hence contributed to the datasets in the manuscript. 
 
 
Fig. VIII. Immunofluorescent analysis of BrdU labelling (red), together with SOX9 (green), and 
DAPI (blue) staining in mouse limb buds at the indicated somite stages (S). Scale bar = 200 
µm. (n ≥ 5 independent experiments). 
 
 
